{
  "GPC3": "GPC3 (Glypican-3) is a heparan sulfate proteoglycan gene that is often overexpressed in various cancers, including non-small cell lung cancer (NSCLC). Its elevated expression has been associated with poor prognosis, as it may promote tumor growth and metastasis through the modulation of cell signaling pathways. Consequently, GPC3 levels could serve as a potential biomarker for stratifying NSCLC patients based on survival outcomes and guiding targeted therapeutic strategies.",
  "MAP2K3": "MAP2K3 (Mitogen-Activated Protein Kinase Kinase 3) is a gene that encodes a protein involved in the MAPK signaling pathway, which plays a critical role in cell proliferation, differentiation, and survival. In the context of non-small cell lung cancer (NSCLC), alterations in MAP2K3 expression or mutations have been associated with tumor progression and resistance to targeted therapies, potentially impacting patient prognosis. Elevated MAP2K3 activity may correlate with poorer survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more personalized treatment approaches.",
  "GUCY1A1": "GUCY1A1 encodes a soluble guanylate cyclase, which is involved in the nitric oxide signaling pathway, and has been implicated in various cancer processes, including NSCLC. Its expression levels have been associated with tumor progression and patient prognosis, where higher GUCY1A1 expression may correlate with improved survival outcomes due to its role in modulating tumor microenvironment and angiogenesis. Understanding GUCY1A1's influence on survival can aid in stratifying patients for targeted therapies and optimizing treatment strategies in NSCLC.",
  "MCTP1": "MCTP1 (Mammalian C-terminal PDZ ligand of the protein tyrosine phosphatase) is a gene that has been implicated in various cellular processes, including cell signaling and adhesion. In the context of non-small cell lung cancer (NSCLC), altered expression of MCTP1 has been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated levels of MCTP1 may correlate with poorer survival outcomes, influencing treatment decisions and highlighting the need for further investigation into its role in NSCLC therapeutic strategies.",
  "FAM13C": "FAM13C is a gene associated with lung cancer susceptibility and has been linked to poor prognosis in NSCLC. Its expression levels may serve as a potential biomarker for survival outcomes in patients.",
  "TENT5C": "TENT5C is an RNA-binding protein implicated in the regulation of mRNA stability and translation. Its expression levels have been associated with poor prognosis in NSCLC, highlighting its potential as a biomarker for survival outcomes.",
  "Stage_IA": "Stage IA NSCLC is characterized by a tumor size \u22643 cm without lymph node involvement. It is clinically significant as patients typically have a favorable prognosis, with higher survival rates compared to advanced stages.",
  "ASB8": "ASB8 (Ankyrin Repeat and SOCS Box-Containing 8) is a gene that encodes a protein involved in the regulation of various signaling pathways, including those related to cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of",
  "ZNF507": "ZNF507 is a gene that encodes a zinc finger protein, which is involved in transcriptional regulation and may play a role in cellular processes such as proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in ZNF507 expression have been associated with poor prognosis",
  "EXOC1": "EXOC1 is a gene that encodes a component of the exocyst complex, which is involved in vesicle trafficking and secretion processes. In the context of non-small cell lung cancer (NSCLC), altered expression of EXOC1 has been associated with tumor progression and poor prognosis, potentially influencing",
  "PFKP": "PFKP (phosphofructokinase, platelet) is a gene that encodes an enzyme involved in glycolysis, a metabolic pathway often upregulated in cancer cells, including non-small cell lung cancer (NSCLC). Elevated expression of PFKP has been associated with poor prognosis in NS",
  "FPR2": "FPR2 (Formyl Peptide Receptor 2) is a G-protein coupled receptor that plays a role in immune response modulation and inflammation. In the context of non-small cell lung cancer (NSCLC), FPR2 has been implicated in tumor progression and immune evasion, with studies",
  "PALB2": "PALB2 (Partner and Localizer of BRCA2) is a gene that plays a critical role in DNA repair through homologous recombination, and its mutations have been implicated in various cancers, including non-small cell lung cancer (NSCLC). In NSCLC, PALB2 mutations are associated",
  "CREG1": "CREG1 (Cellular Regulator of EGF Signaling 1) is a gene that has been implicated in the regulation of cell proliferation and apoptosis, particularly in the context of non-small cell lung cancer (NSCLC). Elevated expression of CREG1 has been associated with poor prognosis in NS",
  "ALDH9A1": "ALDH9A1 is a gene encoding an enzyme involved in the metabolism of aldehydes and the detoxification of reactive oxygen species, which may play a role in cellular stress responses. In the context of non-small cell lung cancer (NSCLC), altered expression of ALDH9A1 has",
  "PDLIM2": "PDLIM2 is a gene that encodes a protein involved in regulating cell signaling and cytoskeletal organization. In the context of non-small cell lung cancer (NSCLC), PDLIM2 has been associated with tumor progression and immune evasion, potentially influencing the effectiveness of immunotherapies. Elevated expression levels of PDLIM2 may correlate with poorer survival outcomes, highlighting its potential as a prognostic biomarker and a target for therapeutic intervention in NSCLC patients.",
  "GPAA1": "GPAA1 (Glycosylphosphatidylinositol Anchor Attachment 1) is a gene implicated in the post-translational modification of proteins, which plays a role in cell signaling and adhesion. In the context of non-small cell lung cancer (NSCLC), altered expression of GPAA1 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of targeted therapies. Elevated levels of GPAA1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "FAAP100": "FAAP100 (Fanconi Anemia Associated Protein 100) is a gene involved in the DNA damage repair pathway, specifically in the Fanconi anemia pathway, which is crucial for maintaining genomic stability. In the context of non-small cell lung cancer (NSCLC), alterations in FAAP100 expression or function have been associated with poor prognosis, as they may lead to increased genomic instability and resistance to DNA-damaging therapies. Consequently, evaluating FAAP100 levels could provide valuable prognostic information and guide treatment decisions, potentially influencing patient survival outcomes by identifying those who may benefit from targeted therapies or more aggressive treatment strategies.",
  "NR3C2": "NR3C2, also known as the mineralocorticoid receptor (MR), is a gene that encodes a receptor involved in the regulation of various physiological processes, including inflammation and cell proliferation. In the context of non-small cell lung cancer (NSCLC), NR3C2 has been implicated in tumor progression and resistance to therapies, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting NR3C2 signaling pathways could offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "MFHAS1": "MFHAS1 (Malignant Fibrous Histiocytoma Amplified Sequence 1) is a gene that has been implicated in the regulation of cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of MFHAS1 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapy. Understanding MFHAS1's role may help identify high-risk patients and guide treatment strategies, ultimately impacting survival outcomes in NSCLC.",
  "ADGRF5": "ADGRF5 (Adhesion G Protein-Coupled Receptor F5) is a gene that encodes a member of the adhesion GPCR family, which is involved in cell signaling and adhesion processes. In the context of non-small cell lung cancer (NSCLC), altered expression of ADGRF5 has been associated with tumor progression and poor prognosis, potentially influencing pathways related to metastasis and immune evasion. Elevated levels of ADGRF5 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "CD79A": "CD79A is a gene that encodes a component of the B-cell receptor complex, playing a crucial role in B-cell signaling and activation. In the context of non-small cell lung cancer (NSCLC), aberrant expression of CD79A has been associated with poor prognosis, potentially influencing tumor immune evasion and response to therapies. Elevated levels of CD79A may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients for targeted immunotherapy approaches.",
  "RBM34": "RBM34 (RNA Binding Motif Protein 34) is a gene that encodes a protein involved in RNA processing and regulation, which has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and patient prognosis, where higher RBM34 expression may correlate with improved survival outcomes due to its potential role in modulating apoptosis and cell cycle regulation. Understanding RBM34's influence on NSCLC could aid in identifying prognostic biomarkers and developing targeted therapies, ultimately impacting patient management and survival strategies.",
  "STAT5A": "STAT5A is a transcription factor gene that plays a crucial role in cell signaling pathways, particularly those related to growth and survival in non-small cell lung cancer (NSCLC). Elevated expression of STAT5A has been associated with poor prognosis, as it may promote tumor proliferation and resistance to apoptosis, thereby influencing treatment responses. Consequently, STAT5A levels could serve as a potential biomarker for predicting patient survival outcomes and tailoring therapeutic strategies in NSCLC.",
  "LDLRAP1": "LDLRAP1 (Low-Density Lipoprotein Receptor Adaptor Protein 1) is a gene involved in lipid metabolism and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), alterations in LDLRAP1 expression have been associated with tumor progression and may influence the efficacy of targeted therapies, potentially impacting patient prognosis. Elevated levels of LDLRAP1 have been linked to poorer survival outcomes, suggesting its role as a prognostic biomarker in NSCLC that could guide treatment decisions.",
  "SQSTM1": "SQSTM1 (sequestosome 1) is a gene that encodes a protein involved in autophagy and cellular stress responses, playing a critical role in the regulation of inflammation and cell survival. In the context of non-small cell lung cancer (NSCLC), alterations in SQSTM1 expression have been associated with poor prognosis, as they may contribute to tumor progression and resistance to therapies. Elevated levels of SQSTM1 can influence patient survival outcomes by promoting tumor cell survival under stress conditions, thereby potentially leading to worse overall survival rates in NSCLC patients.",
  "MRPL20": "MRPL20 (Mitochondrial Ribosomal Protein L20) is a gene encoding a component of the mitochondrial ribosome, which is crucial for protein synthesis within mitochondria. In the context of non-small cell lung cancer (NSCLC), altered expression of MRPL20 has been associated with tumor progression and poor prognosis, potentially influencing metabolic pathways that support cancer cell survival and proliferation. Elevated levels of MRPL20 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "Stage_IB": "\"Stage_IB\" refers to a clinical staging classification in non-small cell lung cancer (NSCLC), indicating a tumor size greater than 3 cm or with specific characteristics, but without lymph node involvement or distant metastasis. This stage is significant as it often correlates with a moderate prognosis, where surgical resection can be curative, yet the risk of recurrence remains, influencing treatment decisions such as adjuvant therapy. Understanding the implications of Stage_IB can help oncologists stratify patients for more personalized management strategies, ultimately impacting survival outcomes.",
  "PDCD1": "PDCD1, commonly known as PD-1, is a gene that encodes a protein involved in the immune checkpoint pathway, playing a critical role in regulating T-cell activity. In the context of non-small cell lung cancer (NSCLC), high expression levels of PDCD1 are associated with poor prognosis, as they can lead to immune evasion by the tumor. Targeting PD-1 with immune checkpoint inhibitors has shown promise in improving survival outcomes for NSCLC patients, particularly those with high PD-L1 expression, highlighting its significance in both prognosis and therapeutic strategies.",
  "SLC38A6": "SLC38A6 is a gene encoding a sodium-coupled neutral amino acid transporter, which has been implicated in the regulation of amino acid metabolism and tumor microenvironment in non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and patient prognosis, with higher SLC38A6 expression correlating with poorer survival outcomes. Targeting SLC38A6 may offer therapeutic potential by modulating metabolic pathways that influence tumor growth and response to treatment, thereby impacting overall patient survival.",
  "ARPP19": "ARPP19 (cAMP-regulated phosphoprotein 19) is a gene that encodes a protein involved in the regulation of cellular signaling pathways, particularly those related to cell proliferation and survival. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of ARPP19 have been associated with poor prognosis, as it may promote tumor growth and resistance to therapies. Consequently, ARPP19 could serve as a potential biomarker for stratifying patient survival outcomes and guiding treatment decisions in NSCLC.",
  "PRPS2": "PRPS2 (phosphoribosyl pyrophosphate synthetase 2) is a gene involved in nucleotide metabolism and is implicated in the proliferation of cancer cells. In the context of non-small cell lung cancer (NSCLC), elevated expression of PRPS2 has been associated with poor prognosis, potentially due to its role in promoting tumor growth and resistance to chemotherapy. Consequently, high PRPS2 levels may negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more aggressive treatment approaches.",
  "MTARC2": "MTARC2 (Mitochondrial Targeting Sequence-Associated Regulator 2) is a gene implicated in mitochondrial function and cellular metabolism. In the context of non-small cell lung cancer (NSCLC), alterations in MTARC2 expression have been associated with tumor progression and resistance to therapies, potentially serving as a prognostic biomarker. Elevated levels of MTARC2 may correlate with poorer survival outcomes, highlighting its potential role in guiding treatment strategies and patient management in NSCLC.",
  "COL2A1": "COL2A1 encodes collagen type II, a structural protein that plays a critical role in the extracellular matrix and tissue integrity. In the context of non-small cell lung cancer (NSCLC), altered expression of COL2A1 has been associated with tumor progression and metastasis, potentially serving as a prognostic marker. Elevated levels of COL2A1 may correlate with poorer survival outcomes, influencing treatment decisions and highlighting the importance of ECM remodeling in NSCLC pathophysiology.",
  "CCDC181": "CCDC181 (Coiled-Coil Domain Containing 181) is a gene that has been implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in CCDC181 expression have been associated with tumor aggressiveness and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of CCDC181 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "MRS2": "MRS2 encodes a mitochondrial magnesium transporter that plays a crucial role in cellular metabolism and mitochondrial function. In the context of non-small cell lung cancer (NSCLC), altered expression of MRS2 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies targeting metabolic pathways. Elevated MRS2 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "FABP6": "FABP6 (Fatty Acid Binding Protein 6) is a gene that encodes a protein involved in fatty acid transport and metabolism, which has been implicated in various cancer types, including non-small cell lung cancer (NSCLC). Elevated expression of FABP6 has been associated with poor prognosis in NSCLC patients, potentially influencing tumor growth and metastasis through altered lipid metabolism. Understanding FABP6 levels may help stratify patients for targeted therapies and improve survival outcomes by identifying those at higher risk for aggressive disease.",
  "ZNF274": "ZNF274 is a zinc finger protein gene that has been implicated in the regulation of gene expression and chromatin remodeling. In the context of non-small cell lung cancer (NSCLC), altered expression of ZNF274 has been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapy. Its expression levels may serve as a biomarker for survival outcomes, with lower levels correlating with reduced overall survival, thereby providing insights for risk stratification and personalized treatment approaches in NSCLC patients.",
  "OSBPL1A": "OSBPL1A (Oxysterol Binding Protein-Like 1A) is a gene that encodes a protein involved in lipid metabolism and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), OSBPL1A has been implicated in tumor progression and may influence the tumor microenvironment, potentially affecting patient prognosis. Elevated expression levels of OSBPL1A have been associated with poorer survival outcomes, suggesting that it could serve as a prognostic biomarker and a potential therapeutic target in NSCLC management.",
  "XPNPEP1": "XPNPEP1 (X-prolyl aminopeptidase) is a gene that encodes an enzyme involved in the processing of peptides and has been implicated in various cancer-related pathways, including those affecting tumor microenvironment and immune response. In the context of non-small cell lung cancer (NSCLC), elevated expression of XPNPEP1 has been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Its role in modulating immune evasion and tumor metabolism may significantly impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for targeted therapies.",
  "SETBP1": "SETBP1 is a gene that encodes a protein involved in regulating transcription and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), mutations in SETBP1 have been associated with poor prognosis, as they may contribute to tumorigenesis and resistance to targeted therapies. Elevated SETBP1 expression levels can influence patient survival outcomes by promoting aggressive tumor behavior and potentially leading to decreased overall survival rates in affected individuals.",
  "DEPTOR": "DEPTOR (DEP domain containing mTOR-interacting protein) is a gene that acts as a negative regulator of the mTOR signaling pathway, which is crucial for cell growth and proliferation. In the context of non-small cell lung cancer (NSCLC), elevated DEPTOR expression has been associated with poor prognosis, as it may contribute to tumor growth and resistance to therapies targeting the mTOR pathway. Consequently, DEPTOR levels could serve as a potential biomarker for predicting patient survival outcomes and guiding treatment strategies in NSCLC.",
  "CGRRF1": "CGRRF1 (Cancer Gene Regulation and Response Factor 1) is a gene implicated in the regulation of cellular responses to stress and apoptosis, which may influence tumor behavior in non-small cell lung cancer (NSCLC). Its expression levels have been associated with patient prognosis, where higher CGRRF1 expression may correlate with improved survival outcomes due to enhanced tumor suppression and response to therapy. Understanding CGRRF1's role could aid in stratifying NSCLC patients for tailored treatment approaches and monitoring disease progression.",
  "CSTF3": "CSTF3 (Cleavage Stimulation Factor Subunit 3) is a gene involved in the regulation of mRNA processing and stability, which has been implicated in the pathogenesis of non-small cell lung cancer (NSCLC). Elevated expression levels of CSTF3 have been associated with poor prognosis in NSCLC patients, potentially influencing tumor aggressiveness and response to therapies. By modulating key pathways related to cell proliferation and apoptosis, CSTF3 may serve as a prognostic biomarker, helping to stratify patients based on their likely survival outcomes and guiding treatment decisions.",
  "Age": "In the context of non-small cell lung cancer (NSCLC) survival analysis, \"Age\" is a clinical variable that represents the chronological age of the patient at diagnosis. It is known to significantly influence prognosis, with younger patients often exhibiting better survival outcomes compared to older patients, potentially due to differences in tumor biology, comorbidities, and treatment tolerance. Age can also impact treatment decisions and the likelihood of receiving aggressive therapies, thereby affecting overall survival rates in NSCLC patients.",
  "AOC4P": "AOC4P (Amine Oxidase, Copper Containing 4 Pseudogene) is a pseudogene associated with the regulation of amine oxidase activity, which may influence tumor microenvironment and immune response in non-small cell lung cancer (NSCLC). While its direct role in NSCLC prognosis is still under investigation, alterations in its expression have been linked to tumor progression and patient survival outcomes, potentially serving as a biomarker for treatment response. Understanding AOC4P's impact on NSCLC could help refine prognostic models and therapeutic strategies, ultimately improving patient management.",
  "S100A14": "S100A14 is a member of the S100 protein family, which is involved in various cellular processes, including cell proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), elevated expression of S100A14 has been associated with poor prognosis, as it may promote tumor growth and metastasis. Its role as a potential biomarker for aggressive disease could influence patient survival outcomes by guiding treatment decisions and monitoring disease progression.",
  "ULK2": "ULK2 (Unc-51 Like Autophagy Activating Kinase 2) is a gene involved in the autophagy pathway, which plays a critical role in cellular homeostasis and response to stress. In the context of non-small cell lung cancer (NSCLC), altered expression of ULK2 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies that target autophagy. Elevated ULK2 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "TGFA": "TGFA (Transforming Growth Factor Alpha) is a gene that encodes a growth factor involved in the regulation of cell proliferation and differentiation, particularly in epithelial tissues. In the context of non-small cell lung cancer (NSCLC), elevated TGFA expression has been associated with poor prognosis, as it may promote tumor growth and metastasis through its role in the epidermal growth factor receptor (EGFR) signaling pathway. Consequently, TGFA levels could serve as a potential biomarker for survival outcomes, influencing treatment decisions and the stratification of patients for targeted therapies.",
  "SSPN": "SSPN (sarcospan) is a gene that encodes a protein involved in muscle cell membrane stability and has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and metastasis, suggesting that SSPN may serve as a potential biomarker for poor prognosis in NSCLC patients. Elevated SSPN expression could influence patient survival outcomes by promoting aggressive tumor behavior, thereby impacting treatment responses and overall survival rates.",
  "LAIR1": "LAIR1 (Leukocyte-associated immunoglobulin-like receptor 1) is a gene that encodes an inhibitory receptor expressed on immune cells, playing a role in modulating immune responses within the tumor microenvironment. In the context of non-small cell lung cancer (NSCLC), LAIR1 has been implicated in tumor immune evasion, with higher expression levels associated with poorer prognosis and reduced survival outcomes due to its potential to inhibit anti-tumor immunity. Targeting LAIR1 or its pathways may enhance the efficacy of immunotherapies, offering a promising avenue for improving patient survival in NSCLC.",
  "CD300A": "CD300A is an immune checkpoint gene that encodes a receptor involved in the regulation of immune responses. In the context of non-small cell lung cancer (NSCLC), elevated expression of CD300A has been associated with poor prognosis, as it may inhibit T-cell activation and promote tumor immune evasion. Targeting CD300A could enhance the efficacy of immunotherapies, potentially improving survival outcomes for NSCLC patients by reinvigorating anti-tumor immune responses.",
  "NEMF": "NEMF (Nuclear Export Mediator Factor) is a gene that encodes a protein involved in the nuclear export of mRNA and has been implicated in various cellular processes, including the regulation of gene expression. In the context of non-small cell lung cancer (NSCLC), alterations in NEMF expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Elevated NEMF levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "SLC9A1": "SLC9A1 (Sodium/Hydrogen Exchanger 1) is a gene that encodes a protein involved in cellular ion transport and pH regulation, which can influence tumor microenvironment and cancer cell behavior. In the context of non-small cell lung cancer (NSCLC), altered expression of SLC9A1 has been associated with tumor progression and may serve as a prognostic biomarker, potentially impacting treatment responses to therapies that target the tumor microenvironment. Elevated SLC9A1 expression may correlate with poorer survival outcomes, highlighting its relevance in stratifying patient prognosis and guiding therapeutic decisions.",
  "NDUFAF3": "NDUFAF3 (NADH:ubiquinone oxidoreductase complex assembly factor 3) is a gene involved in mitochondrial function and oxidative phosphorylation, which plays a critical role in cellular energy metabolism. In the context of non-small cell lung cancer (NSCLC), altered expression of NDUFAF3 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies targeting metabolic pathways. Elevated levels of NDUFAF3 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and therapeutic options.",
  "MBD1": "MBD1 (Methyl-CpG Binding Domain Protein 1) is a gene involved in the regulation of gene expression through DNA methylation, playing a critical role in epigenetic modifications. In the context of non-small cell lung cancer (NSCLC), MBD1 has been associated with tumor progression and poor prognosis, as its expression levels can influence tumor suppressor gene silencing and cancer cell proliferation. Elevated MBD1 expression may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "WFS1": "WFS1 (Wolfram Syndrome 1) is a gene that encodes a protein involved in endoplasmic reticulum stress response and cellular apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of WFS1 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Elevated WFS1 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "ZC3H15": "ZC3H15 is a gene that encodes a zinc finger protein, which has been implicated in various cellular processes, including RNA metabolism and gene regulation. In the context of non-small cell lung cancer (NSCLC), alterations in ZC3H15 expression have been associated with tumor progression and may serve as a prognostic biomarker, influencing patient survival outcomes. Elevated levels of ZC3H15 expression have been linked to poorer survival rates, suggesting its potential role in tumor aggressiveness and response to targeted therapies.",
  "ADAMTSL2": "ADAMTSL2 is a gene encoding a member of the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) family, which is involved in extracellular matrix remodeling and has been implicated in tumor progression. In the context of non-small cell lung cancer (NSCLC), altered expression of ADAMTSL2 has been associated with poor prognosis, potentially influencing tumor invasiveness and metastasis. Its expression levels may serve as a prognostic biomarker, with lower levels correlating with decreased survival outcomes, thereby providing insights for therapeutic strategies targeting the tumor microenvironment.",
  "RFC5": "RFC5 (Replication Factor C Complex Subunit 5) is a gene involved in DNA replication and repair, playing a critical role in maintaining genomic stability. In the context of non-small cell lung cancer (NSCLC), altered expression of RFC5 has been associated with poor prognosis, as it may contribute to tumor progression and resistance to chemotherapy. Elevated RFC5 levels could influence patient survival outcomes by promoting tumor cell proliferation and survival, thereby impacting treatment efficacy and overall survival rates.",
  "RARS1": "RARS1 (arginyl-tRNA synthetase 1) is a gene involved in protein synthesis and has been implicated in various cellular processes, including tumorigenesis. In the context of non-small cell lung cancer (NSCLC), altered expression of RARS1 has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Its role in modulating the tumor microenvironment and response to therapies may impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for targeted treatments.",
  "L2HGDH": "L2HGDH (L-2-hydroxyglutarate dehydrogenase) is a gene involved in the metabolism of L-2-hydroxyglutarate, a metabolite associated with altered cellular metabolism in cancer. In the context of non-small cell lung cancer (NSCLC), L2HGDH expression has been linked to tumor progression and may serve as a prognostic biomarker, with lower levels correlating with poorer survival outcomes. By influencing metabolic pathways, L2HGDH may also impact the efficacy of targeted therapies, thereby affecting overall patient survival.",
  "CHRDL1": "CHRDL1 (Chordin-like 1) is a gene that encodes a protein involved in the regulation of the bone morphogenetic protein (BMP) signaling pathway, which plays a critical role in cellular differentiation and tumor microenvironment modulation. In the context of non-small cell lung cancer (NSCLC), altered expression of CHRDL1 has been associated with tumor progression and poor prognosis, potentially influencing patient survival outcomes by affecting tumor growth and metastasis. Targeting CHRDL1 or its downstream pathways may offer novel therapeutic strategies to improve survival in NSCLC patients.",
  "COLGALT1": "COLGALT1 (Collagen Galactosyltransferase 1) is a gene involved in collagen biosynthesis and extracellular matrix remodeling. In the context of non-small cell lung cancer (NSCLC), altered expression of COLGALT1 has been associated with tumor progression and poor prognosis, potentially influencing the tumor microenvironment and metastatic potential. Elevated levels of COLGALT1 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying risk and guiding therapeutic decisions in NSCLC management.",
  "CTBP2": "CTBP2 (C-terminal binding protein 2) is a gene that encodes a transcriptional co-repressor involved in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), elevated expression of CTBP2 has been associated with poor prognosis, as it may promote tumor growth and metastasis by modulating key signaling pathways. Consequently, high levels of CTBP2 expression could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "SLC30A9": "SLC30A9 is a gene encoding a zinc transporter that plays a critical role in cellular zinc homeostasis, which is essential for various biological processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of SLC30A9 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to chemotherapy and targeted therapies. Elevated levels of SLC30A9 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "FAM117A": "FAM117A is a gene that has been implicated in the regulation of cellular processes such as proliferation and apoptosis, which are critical in the context of non-small cell lung cancer (NSCLC). Recent studies suggest that alterations in FAM117A expression may correlate with poor prognosis and resistance to certain therapies, potentially influencing tumor aggressiveness and patient survival outcomes. Understanding its role could aid in stratifying patients for targeted therapies and improving overall management strategies in NSCLC.",
  "GPR22": "GPR22 is a G protein-coupled receptor gene that has been implicated in various signaling pathways associated with tumor progression in non-small cell lung cancer (NSCLC). Its expression levels have been correlated with patient prognosis, where higher GPR22 expression may be associated with poorer survival outcomes, potentially influencing tumor aggressiveness and response to therapies. Understanding GPR22's role could aid in stratifying patients for targeted treatments and improving personalized management strategies in NSCLC.",
  "EXT1": "EXT1 (exostosin glycosyltransferase 1) is a gene involved in the biosynthesis of heparan sulfate, which plays a critical role in cell signaling and tumor microenvironment modulation. In the context of non-small cell lung cancer (NSCLC), alterations in EXT1 expression have been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated EXT1 levels may influence patient survival outcomes by promoting tumor growth and resistance to therapies, highlighting its potential as a target for therapeutic intervention and a marker for stratifying patient risk.",
  "GNG7": "GNG7 (Guanine Nucleotide Binding Protein Gamma 7) is a gene that encodes a subunit of heterotrimeric G proteins, which are involved in various signaling pathways that regulate cell proliferation and survival. In the context of non-small cell lung cancer (NSCLC), altered expression of GNG7 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of GNG7 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "SEPTIN9": "SEPTIN9 is a gene that encodes a member of the septin family of proteins, which are involved in various cellular processes, including cell division and cytoskeletal organization. In the context of non-small cell lung cancer (NSCLC), SEPTIN9 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Elevated SEPTIN9 expression has been associated with aggressive tumor characteristics, potentially influencing treatment responses and guiding therapeutic strategies in NSCLC patients.",
  "ETV5": "ETV5 is a transcription factor gene that plays a critical role in the regulation of various cellular processes, including proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), ETV5 has been implicated in tumor progression and metastasis, with studies suggesting that its overexpression may correlate with poor prognosis and reduced survival outcomes. Targeting ETV5 or its downstream pathways could offer potential therapeutic strategies, influencing patient survival by potentially reversing aggressive tumor behavior.",
  "LTBP1": "LTBP1 (Latent Transforming Growth Factor Beta Binding Protein 1) is a gene involved in the regulation of TGF-\u03b2 signaling, which plays a critical role in tumor microenvironment modulation and extracellular matrix remodeling in non-small cell lung cancer (NSCLC). Elevated expression of LTBP1 has been associated with poor prognosis, as it may enhance tumor invasiveness and metastasis, thereby negatively impacting patient survival outcomes. Targeting LTBP1 or its pathways could offer potential therapeutic strategies to improve survival in NSCLC patients.",
  "LINC00312": "LINC00312 is a long non-coding RNA (lncRNA) that has been implicated in the regulation of various biological processes, including cell proliferation and apoptosis, which are critical in the context of non-small cell lung cancer (NSCLC). Studies have shown that elevated expression levels of LINC00312 are associated with poor prognosis in NSCLC patients, potentially influencing tumor aggressiveness and resistance to therapy. By modulating key signaling pathways, LINC00312 may serve as a prognostic biomarker, helping to stratify patients based on survival outcomes and guiding treatment decisions.",
  "GAS7": "GAS7 (Growth Arrest-Specific 7) is a gene implicated in various cellular processes, including growth regulation and apoptosis, and has been associated with tumor progression in non-small cell lung cancer (NSCLC). Its expression levels have been correlated with patient prognosis, where higher GAS7 expression may indicate a more aggressive tumor phenotype and poorer survival outcomes. Understanding GAS7's role in NSCLC could inform treatment strategies and help identify patients at higher risk for adverse outcomes, potentially guiding more personalized therapeutic approaches.",
  "TRIM9": "TRIM9 (Tripartite Motif Containing 9) is a gene that encodes a protein involved in various cellular processes, including apoptosis and immune response modulation. In the context of non-small cell lung cancer (NSCLC), TRIM9 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with patient prognosis, potentially serving as a biomarker for survival outcomes. Elevated TRIM9 expression may influence patient survival by promoting tumor aggressiveness, thereby impacting treatment responses and overall clinical outcomes.",
  "ETV4": "ETV4 (E26 transformation-specific variant 4) is a transcription factor that plays a critical role in regulating gene expression associated with cell proliferation and metastasis in non-small cell lung cancer (NSCLC). Elevated ETV4 expression has been linked to poor prognosis, as it is associated with aggressive tumor behavior and resistance to targeted therapies. Consequently, ETV4 may serve as a potential biomarker for stratifying NSCLC patients based on survival outcomes and guiding therapeutic decisions.",
  "SMPD3": "SMPD3 (sphingomyelin phosphodiesterase 3) is a gene involved in sphingolipid metabolism, which has been implicated in various cancer processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of SMPD3 has been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of SMPD3 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "SATB2": "SATB2 (Special AT-rich Sequence-Binding Protein 2) is a gene that encodes a nuclear matrix protein involved in chromatin remodeling and gene expression regulation. In the context of non-small cell lung cancer (NSCLC), SATB2 has been associated with tumor differentiation and may serve as a prognostic marker, with higher expression levels correlating with improved survival outcomes. Its role in modulating immune responses and tumor microenvironment interactions suggests that SATB2 could influence patient survival by affecting tumor aggressiveness and response to therapies.",
  "SCN11A": "SCN11A encodes a sodium channel that is involved in neuronal excitability and has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and may influence the efficacy of certain chemotherapeutic agents, potentially impacting patient survival outcomes. Elevated SCN11A expression could correlate with poorer prognosis, suggesting its role as a biomarker for stratifying NSCLC patients based on their risk and treatment response.",
  "NDUFA10": "NDUFA10 is a gene that encodes a subunit of the mitochondrial NADH dehydrogenase complex, playing a critical role in oxidative phosphorylation and energy metabolism. In the context of non-small cell lung cancer (NSCLC), alterations in NDUFA10 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies targeting metabolic pathways. Elevated levels of NDUFA10 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "NCOA2": "NCOA2 (Nuclear Receptor Coactivator 2) is a gene that encodes a coactivator involved in the transcriptional regulation of steroid hormone receptors and is implicated in various signaling pathways associated with cancer progression. In non-small cell lung cancer (NSCLC), NCOA2 has been associated with poor prognosis, as its overexpression can promote tumor growth and metastasis, potentially influencing treatment resistance to targeted therapies. Elevated levels of NCOA2 may correlate with decreased patient survival outcomes, making it a potential biomarker for stratifying risk and guiding therapeutic decisions in NSCLC management.",
  "CDKN1C": "CDKN1C (Cyclin-Dependent Kinase Inhibitor 1C) is a gene that encodes a protein involved in cell cycle regulation, specifically inhibiting cyclin-dependent kinases. In the context of non-small cell lung cancer (NSCLC), altered expression of CDKN1C has been associated with poor prognosis, as it may contribute to uncontrolled cell proliferation and tumor progression. Its expression levels could serve as a potential biomarker for survival outcomes, influencing treatment decisions and patient management strategies in NSCLC.",
  "TBC1D5": "TBC1D5 is a gene that encodes a protein involved in the regulation of intracellular trafficking and autophagy, which are critical processes in cancer cell metabolism and survival. In the context of non-small cell lung cancer (NSCLC), alterations in TBC1D5 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of TBC1D5 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "STX5": "STX5 (Syntaxin 5) is a gene that encodes a protein involved in vesicular transport and membrane fusion, playing a critical role in cellular processes such as secretion and protein trafficking. In the context of non-small cell lung cancer (NSCLC), altered expression of STX5 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated STX5 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "XYLT2": "XYLT2 (xylosyltransferase 2) is a gene involved in glycosaminoglycan biosynthesis, which plays a role in the extracellular matrix and cell signaling. In the context of non-small cell lung cancer (NSCLC), altered expression of XYLT2 has been associated with tumor progression and poor prognosis, potentially influencing the tumor microenvironment and metastatic potential. Elevated levels of XYLT2 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for targeted therapies and monitoring disease progression.",
  "TAF2": "TAF2 (TATA-box binding protein associated factor 2) is a gene that encodes a protein involved in the transcriptional regulation of various genes, including those implicated in cell cycle control and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of TAF2 has been associated with poor prognosis, potentially influencing tumor growth and response to therapies. Elevated levels of TAF2 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients for more personalized treatment approaches.",
  "FOSL2": "FOSL2 is a gene that encodes a transcription factor involved in the regulation of cell proliferation and apoptosis, playing a significant role in the tumorigenesis of non-small cell lung cancer (NSCLC). Elevated expression levels of FOSL2 have been associated with poor prognosis and aggressive tumor behavior, potentially influencing treatment responses and survival outcomes in NSCLC patients. Targeting FOSL2 or its downstream pathways may offer therapeutic strategies to improve survival in this patient population.",
  "TUBAL3": "TUBAL3, also known as TUBB3, is a gene encoding a class III beta-tubulin protein, which is involved in microtubule dynamics and cellular processes such as mitosis and intracellular transport. In the context of non-small cell lung cancer (NSCLC), high expression levels of TUBAL3 have been associated with poor prognosis and resistance to certain chemotherapeutic agents, particularly taxanes. Consequently, TUBAL3 expression may serve as a potential biomarker for predicting patient survival outcomes and guiding treatment strategies in NSCLC.",
  "MYO3A": "MYO3A is a gene encoding a myosin motor protein that has been implicated in various cellular processes, including cell motility and signaling. In the context of non-small cell lung cancer (NSCLC), alterations in MYO3A expression have been associated with tumor progression and metastasis, suggesting its potential role as a prognostic biomarker. Elevated MYO3A levels may correlate with poorer survival outcomes, indicating that it could serve as a therapeutic target or a stratification factor for treatment decisions in NSCLC patients.",
  "GMFB": "GMFB (Glial Membrane Protein B) is a gene that has been implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of GMFB has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Its role in modulating immune responses may also affect patient survival outcomes, as higher GMFB expression could correlate with a more aggressive disease phenotype and reduced overall survival.",
  "HINFP": "HINFP (HIN-1 Interacting Protein) is a gene that has been implicated in various cellular processes, including RNA metabolism and regulation of gene expression. In the context of non-small cell lung cancer (NSCLC), altered expression of HINFP has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Elevated levels of HINFP may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "ZNF302": "ZNF302 is a gene that encodes a zinc finger protein, which is involved in transcriptional regulation and may play a role in cellular processes such as proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of ZNF302 has been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of ZNF302 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "KDSR": "KDSR (Keto-Dihydroxy-3-Methylbutyric Acid Reductase) is a gene involved in the metabolism of branched-chain amino acids and has been implicated in cancer metabolism. In the context of non-small cell lung cancer (NSCLC), altered expression of KDSR may influence tumor growth and response to therapies, potentially serving as a prognostic biomarker. Elevated levels of KDSR have been associated with poorer survival outcomes, suggesting that it may play a role in tumor aggressiveness and treatment resistance, thereby impacting patient survival.",
  "SCN7A": "SCN7A encodes a sodium channel that is involved in regulating cellular excitability and signaling. In the context of non-small cell lung cancer (NSCLC), alterations in SCN7A expression have been associated with tumor progression and metastasis, potentially influencing patient prognosis. Elevated SCN7A expression may correlate with poorer survival outcomes, suggesting its potential as a biomarker for aggressive disease and a target for therapeutic intervention.",
  "URGCP": "URGCP (Upregulated Gene in Colorectal Cancer 1) is a gene that has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its overexpression has been associated with poor prognosis, as it may promote tumor growth and metastasis through mechanisms such as cell proliferation and resistance to apoptosis. Consequently, high levels of URGCP expression in NSCLC patients could serve as a potential biomarker for adverse survival outcomes, influencing treatment decisions and patient management strategies.",
  "CTNND1": "CTNND1 (Catenin Delta 1) is a gene that encodes a protein involved in cell adhesion and signaling pathways, particularly in the context of epithelial-mesenchymal transition (EMT), which is crucial in cancer progression. In non-small cell lung cancer (NSCLC), alterations in CTNND1 expression have been associated with poor prognosis, as they may contribute to tumor invasiveness and metastasis. Consequently, high levels of CTNND1 expression could negatively influence patient survival outcomes by promoting aggressive tumor behavior and resistance to therapies.",
  "KLHL2": "KLHL2 (Kelch-like protein 2) is a gene that encodes a protein involved in the regulation of cellular processes, including protein degradation and stress response. In the context of non-small cell lung cancer (NSCLC), altered expression of KLHL2 has been associated with tumor progression and poor prognosis, potentially influencing pathways related to cell cycle regulation and apoptosis. Elevated KLHL2 levels may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "APAF1": "APAF1 (apoptosis protease-activating factor 1) is a gene that plays a crucial role in the intrinsic apoptotic pathway, facilitating programmed cell death. In the context of non-small cell lung cancer (NSCLC), alterations in APAF1 expression have been associated with tumor progression and resistance to chemotherapy, impacting patient prognosis. High levels of APAF1 expression may correlate with improved survival outcomes, as it suggests a more effective apoptotic response to treatment, while low expression could indicate a more aggressive disease phenotype and poorer survival.",
  "AVPR1A": "AVPR1A encodes the vasopressin receptor 1A, which is involved in various physiological processes, including vasoconstriction and fluid balance. In the context of non-small cell lung cancer (NSCLC), altered expression of AVPR1A has been associated with tumor progression and may influence the tumor microenvironment, potentially affecting patient prognosis. Higher levels of AVPR1A expression have been linked to poorer survival outcomes, suggesting that it could serve as a prognostic biomarker and a potential therapeutic target in NSCLC management.",
  "TXLNGY": "TXLNGY (Taxilin gamma) is a gene that encodes a protein involved in intracellular transport and signaling pathways. In the context of non-small cell lung cancer (NSCLC), alterations in TXLNGY expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of TXLNGY may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and guiding therapeutic decisions.",
  "ITGBL1": "ITGBL1 (Integrin Beta-Like 1) is a gene that encodes a protein involved in cell adhesion and extracellular matrix interactions, playing a role in tumor progression and metastasis in non-small cell lung cancer (NSCLC). Elevated expression of ITGBL1 has been associated with poor prognosis, as it may enhance tumor invasiveness and resistance to therapies. Consequently, high levels of ITGBL1 could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients in clinical settings.",
  "SLC52A1": "SLC52A1 encodes a riboflavin transporter that plays a crucial role in cellular metabolism and energy production. In the context of non-small cell lung cancer (NSCLC), altered expression of SLC52A1 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies that target metabolic pathways. Elevated levels of SLC52A1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "YWHAH": "YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta) is a gene that encodes a protein involved in various cellular processes, including signal transduction and cell cycle regulation. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of YWHAH have been associated with poor prognosis, potentially due to its role in promoting tumor growth and metastasis. Consequently, YWHAH expression may serve as a prognostic biomarker, influencing patient survival outcomes by identifying individuals at higher risk for aggressive disease and guiding treatment strategies.",
  "ACAP1": "ACAP1 (ArfGAP with coiled-coil, ANK repeat, and PH domains 1) is a gene that encodes a protein involved in the regulation of endocytosis and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), ACAP1 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting ACAP1 or its associated pathways could offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "LRRC31": "LRRC31 (Leucine-Rich Repeat Containing 31) is a gene that has been implicated in the regulation of cell adhesion and signaling pathways, which are critical in tumor progression and metastasis in non-small cell lung cancer (NSCLC). Studies suggest that altered expression of LRRC31 may correlate with poor prognosis, as it can influence tumor aggressiveness and response to therapies. Consequently, assessing LRRC31 expression levels could provide valuable prognostic information and potentially guide treatment strategies, impacting patient survival outcomes in NSCLC.",
  "DOK4": "DOK4 (Docking Protein 4) is a gene that encodes a protein involved in intracellular signaling pathways, particularly those related to cell growth and survival. In the context of non-small cell lung cancer (NSCLC), DOK4 has been implicated in tumor progression and may serve as a potential biomarker for prognosis, with alterations in its expression correlating with poor survival outcomes. Understanding DOK4's role could aid in stratifying patients for targeted therapies and improving overall treatment strategies in NSCLC.",
  "SIGLEC6": "SIGLEC6 is a gene that encodes a sialic acid-binding immunoglobulin-like lectin, which is involved in immune regulation and may play a role in tumor microenvironment interactions. In the context of non-small cell lung cancer (NSCLC), elevated expression of SIGLEC6 has been associated with poor prognosis, potentially due to its involvement in immune evasion mechanisms that allow tumors to escape immune surveillance. Consequently, targeting SIGLEC6 or its pathways may offer novel therapeutic strategies to improve patient survival outcomes by enhancing anti-tumor immunity.",
  "BUB1": "BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) is a gene that encodes a protein involved in the spindle assembly checkpoint, ensuring proper chromosome segregation during cell division. In the context of non-small cell lung cancer (NSCLC), aberrations in BUB1 expression or function have been associated with poor prognosis, as they can lead to genomic instability and tumor progression. Elevated BUB1 levels may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for aggressive disease and a target for therapeutic intervention.",
  "DMXL2": "DMXL2 (Dmx-like 2) is a gene that has been implicated in various cellular processes, including transcriptional regulation and cell proliferation. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of DMXL2 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Consequently, DMXL2 may serve as a prognostic biomarker, where its expression levels could help stratify patients based on survival outcomes and guide treatment decisions.",
  "NYNRIN": "NYNRIN is a gene that has been implicated in various biological processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in NYNRIN expression have been associated with poor prognosis and may influence tumor aggressiveness and response to therapy. Understanding its role could help stratify patients based on survival outcomes and guide targeted treatment strategies.",
  "OSBPL8": "OSBPL8 (Oxysterol Binding Protein-Like 8) is a gene that encodes a protein involved in lipid metabolism and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), OSBPL8 has been implicated in tumor progression and may influence the tumor microenvironment, potentially affecting patient prognosis. Elevated expression levels of OSBPL8 have been associated with poorer survival outcomes, suggesting that it could serve as a prognostic biomarker and a potential therapeutic target in NSCLC management.",
  "PDE10A": "PDE10A (phosphodiesterase 10A) is a gene that encodes an enzyme involved in the degradation of cyclic nucleotides, which play critical roles in cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), altered expression of PDE10A has been associated with tumor progression and may influence the efficacy of targeted therapies, potentially serving as a prognostic biomarker. Elevated PDE10A levels could correlate with poorer survival outcomes, highlighting its potential as a therapeutic target and a factor in stratifying patient risk.",
  "Stage_II": "The feature \"Stage_II\" represents a clinical variable indicating that non-small cell lung cancer (NSCLC) is classified as stage II, where the tumor is larger and may have spread to nearby lymph nodes but not to distant sites. This stage is significant in NSCLC prognosis, as it typically correlates with a moderate risk of metastasis and can influence treatment decisions, such as the need for surgical intervention and adjuvant therapies. Patients with stage II NSCLC generally have a variable survival outcome, with 5-year survival rates ranging from 30% to 60%, depending on factors like tumor size, lymph node involvement, and response to treatment.",
  "PACSIN2": "PACSIN2 (Protein Kinase C and Casein Kinase Substrate in Neurons 2) is a gene involved in endocytosis and cytoskeletal dynamics, which has been implicated in the progression of non-small cell lung cancer (NSCLC). Elevated expression levels of PACSIN2 have been associated with poor prognosis, potentially influencing tumor aggressiveness and metastasis. Understanding PACSIN2's role in NSCLC may provide insights into targeted therapies and help stratify patients based on their survival outcomes.",
  "TPM3": "TPM3 (tropomyosin 3) is a gene that encodes a protein involved in cytoskeletal organization and cellular motility, which can influence tumor progression in non-small cell lung cancer (NSCLC). Alterations in TPM3 expression have been associated with poor prognosis, as they may contribute to increased metastatic potential and resistance to therapies. Consequently, evaluating TPM3 levels could provide valuable prognostic information and help tailor treatment strategies to improve patient survival outcomes in NSCLC.",
  "GRAMD1B": "GRAMD1B (GRAM domain-containing protein 1B) is a gene implicated in the regulation of lipid metabolism and cellular signaling pathways, which has been associated with tumor progression in non-small cell lung cancer (NSCLC). Elevated expression levels of GRAMD1B have been linked to poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Understanding its role may help identify patients at higher risk for adverse outcomes, guiding more personalized treatment strategies in NSCLC management.",
  "TDO2": "TDO2 (tryptophan 2,3-dioxygenase) is an enzyme involved in the kynurenine pathway of tryptophan metabolism, which has been implicated in immune evasion and tumor progression in non-small cell lung cancer (NSCLC). Elevated TDO2 expression has been associated with poor prognosis, as it may promote tumor growth and metastasis by facilitating an immunosuppressive microenvironment. Consequently, targeting TDO2 could enhance the efficacy of immunotherapies and improve survival outcomes for NSCLC patients.",
  "MOB4": "MOB4 (MOB kinase activator 4) is a gene that plays a role in the regulation of the Hippo signaling pathway, which is involved in cell growth and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of MOB4 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of MOB4 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "ECHDC1": "ECHDC1 (Enoyl-CoA hydratase domain-containing 1) is a gene involved in fatty acid metabolism and mitochondrial function. In the context of non-small cell lung cancer (NSCLC), altered expression of ECHDC1 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies targeting metabolic pathways. Elevated levels of ECHDC1 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "PLAC8": "PLAC8 (Placenta-specific 8) is a gene that has been implicated in various cellular processes, including cell proliferation and migration, and is associated with tumor progression in non-small cell lung cancer (NSCLC). Elevated expression levels of PLAC8 have been correlated with poor prognosis and reduced survival outcomes in NSCLC patients, suggesting its potential role as a biomarker for aggressive disease and a target for therapeutic intervention. By influencing tumor growth and metastasis, PLAC8 may serve as a critical factor in stratifying patient risk and guiding treatment decisions.",
  "HOXA10": "HOXA10 is a homeobox gene that plays a critical role in regulating developmental processes and has been implicated in tumorigenesis. In the context of non-small cell lung cancer (NSCLC), elevated expression of HOXA10 has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Its expression levels may serve as a prognostic biomarker, helping to stratify patients based on survival outcomes and guiding therapeutic decisions.",
  "B9D1": "B9D1 (B9 domain-containing protein 1) is a gene that has been implicated in various cellular processes, including cilia formation and signaling pathways. In the context of non-small cell lung cancer (NSCLC), alterations in B9D1 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of B9D1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and therapeutic options.",
  "NBL1": "NBL1 (Neuroblastoma 1) is a gene that has been implicated in the regulation of tumor microenvironment and immune response in non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and patient prognosis, where higher NBL1 expression may correlate with improved survival outcomes due to enhanced immune surveillance. Understanding NBL1's role could inform therapeutic strategies, particularly in immunotherapy, by identifying patients who may benefit from treatments that leverage immune system activation.",
  "C1orf115": "C1orf115, also known as \"Chromosome 1 Open Reading Frame 115,\" is a gene that has been implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in C1orf115 expression have been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of C1orf115 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more personalized treatment approaches.",
  "ANKRD7": "ANKRD7 (Ankyrin Repeat Domain 7) is a gene that has been implicated in various cellular processes, including cell cycle regulation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in ANKRD7 expression have been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of ANKRD7 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "HJURP": "HJURP (Holliday Junction Recognition Protein) is a gene that plays a critical role in the assembly of the centromere and is involved in chromosomal stability. In the context of non-small cell lung cancer (NSCLC), elevated expression of HJURP has been associated with poor prognosis, as it may contribute to tumor aggressiveness and resistance to therapy. Consequently, HJURP expression levels could serve as a potential biomarker for predicting patient survival outcomes and guiding treatment strategies in NSCLC.",
  "PSTPIP2": "PSTPIP2 (proline-serine-threonine phosphatase interacting protein 2) is a gene that has been implicated in the regulation of immune responses and inflammation, which are critical in the tumor microenvironment of non-small cell lung cancer (NSCLC). Elevated expression levels of PSTPIP2 have been associated with poor prognosis in NSCLC patients, potentially due to its role in promoting tumor progression and immune evasion. Understanding PSTPIP2's influence on patient survival outcomes may provide insights into novel therapeutic strategies aimed at modulating immune responses in NSCLC.",
  "ASIC3": "ASIC3 (Acid-Sensing Ion Channel 3) is a gene that encodes a protein involved in the regulation of pH and ion homeostasis, which has been implicated in tumor microenvironment modulation in non-small cell lung cancer (NSCLC). Elevated expression of ASIC3 has been associated with poor prognosis, potentially influencing tumor growth, metastasis, and resistance to therapies. Understanding ASIC3's role may help identify patients at higher risk for adverse outcomes and guide targeted therapeutic strategies to improve survival rates in NSCLC.",
  "AGTR2": "AGTR2 (Angiotensin II Receptor Type 2) is a gene that encodes a receptor involved in the renin-angiotensin system, which plays a role in regulating blood pressure and fluid balance. In the context of non-small cell lung cancer (NSCLC), AGTR2 has been implicated in tumor progression and angiogenesis, with studies suggesting that its expression levels may correlate with patient prognosis and response to therapies. Higher AGTR2 expression has been associated with improved survival outcomes, potentially due to its role in modulating tumor microenvironment and immune response, making it a candidate for further investigation as a therapeutic target or prognostic biomarker in NSCLC.",
  "GLUL": "GLUL (glutamate-ammonia ligase) is a gene that encodes an enzyme involved in the synthesis of glutamine, a critical amino acid for tumor metabolism and growth. In the context of non-small cell lung cancer (NSCLC), elevated GLUL expression has been associated with poor prognosis, as it may promote tumor survival and resistance to therapy by supporting the metabolic demands of cancer cells. Consequently, targeting GLUL or its metabolic pathways could offer potential therapeutic strategies to improve survival outcomes in NSCLC patients.",
  "CCR3": "CCR3 (C-C chemokine receptor type 3) is a gene that encodes a receptor involved in the immune response and inflammation, playing a role in the recruitment of eosinophils and other immune cells to sites of tissue damage. In the context of non-small cell lung cancer (NSCLC), elevated CCR3 expression has been associated with poor prognosis, as it may facilitate tumor progression and metastasis by modulating the tumor microenvironment. Consequently, targeting CCR3 could influence patient survival outcomes by potentially enhancing anti-tumor immunity and improving responses to immunotherapy.",
  "UFL1": "UFL1 (Ubiquitin-Fold Modifier 1) is a gene involved in the regulation of protein degradation and cellular stress responses, which has been implicated in the pathogenesis of non-small cell lung cancer (NSCLC). Elevated expression levels of UFL1 have been associated with poor prognosis in NSCLC patients, potentially influencing tumor growth and resistance to therapies. By modulating the tumor microenvironment and affecting apoptotic pathways, UFL1 may serve as a prognostic biomarker, helping to stratify patients based on their likely survival outcomes and response to treatment.",
  "LPP": "LPP (lipoma-preferred partner) is a gene that encodes a protein involved in cell adhesion and cytoskeletal organization, which has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Elevated expression of LPP has been associated with poor prognosis in NSCLC, potentially influencing tumor progression and metastasis. Understanding LPP's role may aid in stratifying patients for targeted therapies and improving survival outcomes through personalized treatment approaches.",
  "STIM1": "STIM1 (Stromal Interaction Molecule 1) is a gene that encodes a calcium-sensing protein involved in calcium signaling pathways, which are critical for various cellular processes, including proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), elevated STIM1 expression has been associated with poor prognosis, as it may promote tumor growth and metastasis by enhancing calcium influx and supporting cancer cell survival. Consequently, high STIM1 levels could serve as a potential biomarker for reduced patient survival outcomes, highlighting its relevance in therapeutic strategies targeting calcium signaling in NSCLC.",
  "CSNK1E": "CSNK1E (Casein Kinase 1 Epsilon) is a gene that encodes a serine/threonine kinase involved in various cellular processes, including the regulation of the Wnt signaling pathway, which is crucial in cancer development. In the context of non-small cell lung cancer (NSCLC), altered expression of CSNK1E has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of CSNK1E may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "B2M": "B2M (Beta-2-microglobulin) is a gene that encodes a component of the major histocompatibility complex (MHC) class I molecules, playing a crucial role in immune response. In the context of non-small cell lung cancer (NSCLC), elevated levels of B2M have been associated with poor prognosis, as they may indicate increased tumor burden and immune evasion. Consequently, B2M levels can influence patient survival outcomes by serving as a potential biomarker for disease progression and response to immunotherapy.",
  "LY96": "LY96, also known as MD-2, is a gene that encodes a protein involved in the innate immune response, specifically in the recognition of lipopolysaccharides by Toll-like receptor 4 (TLR4). In the context of non-small cell lung cancer (NSCLC), elevated expression of LY96 has been associated with poor prognosis, potentially due to its role in promoting tumor-associated inflammation and immune evasion. Consequently, variations in LY96 expression may influence patient survival outcomes by affecting tumor progression and response to immunotherapy.",
  "C9orf40": "C9orf40 is a gene that has been implicated in various cellular processes, including cell proliferation and apoptosis, and its expression levels have been associated with the prognosis of non-small cell lung cancer (NSCLC). Elevated expression of C9orf40 has been linked to poorer survival outcomes in NSCLC patients, potentially influencing tumor aggressiveness and response to therapies. Understanding its role could aid in stratifying patients for more personalized treatment approaches and improving survival predictions.",
  "MS4A4A": "MS4A4A is a gene that encodes a member of the membrane-spanning 4-domains, subfamily A, which is involved in immune regulation. In the context of non-small cell lung cancer (NSCLC), MS4A4A has been associated with tumor microenvironment modulation and immune evasion, potentially influencing the effectiveness of immunotherapies. Elevated expression levels of MS4A4A may correlate with poorer survival outcomes, highlighting its potential as a prognostic biomarker and a target for therapeutic strategies aimed at enhancing anti-tumor immunity.",
  "ADAM5": "ADAM5 (A Disintegrin and Metalloproteinase 5) is a gene encoding a protein involved in cell adhesion and extracellular matrix remodeling, which plays a role in tumor progression and metastasis in non-small cell lung cancer (NSCLC). Elevated expression of ADAM5 has been associated with poor prognosis, as it may enhance tumor invasiveness and resistance to therapies. Consequently, ADAM5 levels could serve as a potential biomarker for predicting survival outcomes in NSCLC patients, guiding treatment decisions and monitoring disease progression.",
  "VGF": "VGF (VGF nerve growth factor inducible) is a neuropeptide precursor gene that has been implicated in various cancer types, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and poor prognosis, potentially influencing pathways related to tumor growth, metastasis, and resistance to therapy. Elevated VGF expression may correlate with decreased patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "HMBOX1": "HMBOX1 is a gene that encodes a homeobox protein involved in transcriptional regulation and has been implicated in various cancer processes, including NSCLC. Its expression levels have been associated with tumor progression and poor prognosis, suggesting that HMBOX1 may play a role in promoting aggressive tumor behavior. Elevated HMBOX1 expression could potentially influence patient survival outcomes by contributing to tumor metastasis and resistance to therapies, making it a candidate for further investigation in prognostic models and targeted treatments in NSCLC.",
  "EFCC1": "EFCC1 (E3 ubiquitin-protein ligase EFCC1) is a gene implicated in the regulation of cellular processes such as apoptosis and cell cycle progression. In the context of non-small cell lung cancer (NSCLC), alterations in EFCC1 expression have been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of EFCC1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients for more personalized treatment approaches.",
  "ABCA11P": "ABCA11P is a pseudogene associated with the ATP-binding cassette (ABC) transporter family, which is implicated in lipid metabolism and drug resistance mechanisms. In the context of non-small cell lung cancer (NSCLC), aberrant expression of ABCA11P has been linked to poor prognosis, potentially influencing tumor aggressiveness and response to chemotherapy. Elevated levels of this pseudogene may correlate with decreased patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients in clinical settings.",
  "KCNJ16": "KCNJ16 is a gene encoding a potassium ion channel that has been implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in KCNJ16 expression have been associated with tumor progression and may influence the efficacy of targeted therapies. Elevated or aberrant expression of KCNJ16 could serve as a prognostic marker, potentially correlating with poorer survival outcomes in NSCLC patients, thereby guiding treatment decisions and patient management strategies.",
  "MYG1": "MYG1 is a gene that encodes a transcription factor involved in cell cycle regulation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in MYG1 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated MYG1 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "PRPF39": "PRPF39 is a gene involved in pre-mRNA splicing, which plays a critical role in gene expression regulation. In the context of non-small cell lung cancer (NSCLC), altered expression of PRPF39 has been associated with poor prognosis, potentially influencing tumor progression and response to therapies. Elevated levels of PRPF39 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "EIF4H": "EIF4H (Eukaryotic Translation Initiation Factor 4H) is a gene involved in the regulation of protein synthesis, playing a critical role in the translation initiation process. In the context of non-small cell lung cancer (NSCLC), EIF4H has been associated with poor prognosis, as its overexpression may enhance tumor growth and resistance to therapies by promoting the translation of oncogenic proteins. Consequently, elevated levels of EIF4H could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "RACK1": "RACK1 (Receptor for Activated C Kinase 1) is a gene that encodes a scaffolding protein involved in various signaling pathways, including those regulating cell proliferation and survival. In the context of non-small cell lung cancer (NSCLC), RACK1 has been implicated in tumor progression and metastasis, with studies suggesting that its overexpression correlates with poor prognosis and reduced survival outcomes. Targeting RACK1 or its associated pathways may offer therapeutic strategies to improve patient survival by inhibiting tumor growth and enhancing chemosensitivity.",
  "NDRG1": "NDRG1 (N-Myc Downstream Regulated Gene 1) is a gene involved in various cellular processes, including differentiation, stress response, and tumor progression. In the context of non-small cell lung cancer (NSCLC), NDRG1 has been associated with tumor metastasis and poor prognosis, as its expression levels can influence cancer cell invasiveness and resistance to chemotherapy. Elevated NDRG1 expression may correlate with worse survival outcomes in NSCLC patients, making it a potential biomarker for stratifying risk and guiding treatment decisions.",
  "ACTR1A": "ACTR1A (Actin Cytoskeletal Regulator 1A) is a gene that encodes a protein involved in the regulation of microtubule dynamics and cellular transport processes. In the context of non-small cell lung cancer (NSCLC), aberrations in ACTR1A expression have been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated levels of ACTR1A may correlate with poorer survival outcomes, influencing treatment decisions and highlighting the need for targeted therapies that address its role in tumor biology.",
  "BEX1": "BEX1 (Brain Expressed X-Linked 1) is a gene that has been implicated in the regulation of apoptosis and cell proliferation, with emerging evidence suggesting its role in the pathogenesis of non-small cell lung cancer (NSCLC). Studies have shown that altered expression levels of BEX1 may correlate with tumor aggressiveness and patient prognosis, potentially serving as a biomarker for survival outcomes. Elevated BEX1 expression has been associated with poorer survival rates, indicating that it may influence treatment responses and inform therapeutic strategies in NSCLC management.",
  "TUBGCP3": "TUBGCP3 (Tubulin Gamma Complex Protein 3) is a gene that encodes a protein involved in microtubule organization and spindle assembly, playing a critical role in cell division. In the context of non-small cell lung cancer (NSCLC), altered expression of TUBGCP3 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to chemotherapy and targeted therapies. Elevated levels of TUBGCP3 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "P4HA2": "P4HA2 (Prolyl 4-hydroxylase subunit alpha 2) is a gene involved in collagen synthesis and the hypoxic response, playing a critical role in tumor microenvironment remodeling. In non-small cell lung cancer (NSCLC), elevated expression of P4HA2 has been associated with poor prognosis, as it may enhance tumor aggressiveness and metastasis through its influence on extracellular matrix dynamics and angiogenesis. Consequently, targeting P4HA2 could offer therapeutic potential, potentially improving survival outcomes by disrupting these pro-tumorigenic processes.",
  "ASPA": "ASPA (aspartoacylase) is a gene involved in the metabolism of N-acetylaspartate, and its expression has been implicated in various cancers, including non-small cell lung cancer (NSCLC). In NSCLC, altered ASPA expression has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Elevated ASPA levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "KCNJ15": "KCNJ15 is a gene encoding a potassium ion channel that has been implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in KCNJ15 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of KCNJ15 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients in clinical settings.",
  "GPR25": "GPR25 is a G protein-coupled receptor gene that has been implicated in various signaling pathways associated with tumor progression in non-small cell lung cancer (NSCLC). Its expression levels have been correlated with patient prognosis, where higher GPR25 expression may be associated with poorer survival outcomes, potentially influencing treatment responses to targeted therapies. Understanding GPR25's role could aid in stratifying patients for more personalized therapeutic approaches and improving survival predictions in NSCLC.",
  "ADH1C": "ADH1C (Alcohol Dehydrogenase 1C) is a gene encoding an enzyme involved in alcohol metabolism, which has been implicated in the metabolic pathways of various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and patient prognosis, with higher ADH1C expression linked to improved survival outcomes in NSCLC patients, potentially due to its role in modulating the tumor microenvironment and influencing therapeutic responses. Understanding ADH1C's impact on survival can aid in stratifying patients for personalized treatment approaches and monitoring disease progression.",
  "TRIO": "TRIO (Transforming, acidic, coiled-coil-containing protein 1) is a gene that encodes a guanine nucleotide exchange factor involved in Rho GTPase signaling pathways, which are critical for cell migration and proliferation. In the context of non-small cell lung cancer (NSCLC), alterations in TRIO expression or mutations have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated TRIO levels may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "NCOA6": "NCOA6 (Nuclear Receptor Coactivator 6) is a gene that encodes a coactivator involved in the transcriptional regulation of nuclear hormone receptors, playing a role in cellular proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), alterations in NCOA6 expression have been associated with poor prognosis and may influence tumor growth and metastasis, potentially impacting treatment responses to targeted therapies. Elevated NCOA6 levels could correlate with decreased patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more personalized therapeutic approaches.",
  "FKTN": "FKTN (fukutin) is a gene involved in glycosylation processes and is implicated in muscle and neuronal development. In the context of non-small cell lung cancer (NSCLC), altered expression of FKTN has been associated with tumor progression and poor prognosis, potentially influencing pathways related to cell adhesion and metastasis. Elevated levels of FKTN may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "DIO2": "DIO2 (Deiodinase, iodothyronine, type II) is a gene that encodes an enzyme involved in the activation of thyroid hormones, which play a crucial role in cellular metabolism and growth. In the context of non-small cell lung cancer (NSCLC), altered expression of DIO2 has been associated with tumor progression and may influence the efficacy of certain therapies, particularly those targeting metabolic pathways. Elevated DIO2 levels have been linked to poorer survival outcomes, suggesting that it may serve as a potential biomarker for prognosis and a therapeutic target in NSCLC management.",
  "FST": "FST (Follistatin) is a gene that encodes a glycoprotein involved in the regulation of various growth factors, including those in the TGF-beta superfamily, which play a critical role in tumor progression and immune response modulation in non-small cell lung cancer (NSCLC). Elevated levels of FST have been associated with poor prognosis in NSCLC patients, as it may promote tumor growth and metastasis by inhibiting apoptosis and enhancing angiogenesis. Consequently, FST expression levels could serve as a potential biomarker for survival outcomes, guiding treatment decisions and therapeutic strategies in NSCLC management.",
  "PWWP3A": "PWWP3A is a gene that encodes a protein involved in chromatin remodeling and gene expression regulation, which has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Elevated expression levels of PWWP3A have been associated with poor prognosis in NSCLC patients, potentially influencing tumor aggressiveness and resistance to therapies. Understanding its role may help identify patients at higher risk for adverse outcomes and guide treatment strategies, making it a relevant biomarker in survival analysis.",
  "PSG6": "PSG6 (Pregnancy-Specific Glycoprotein 6) is a gene that has been implicated in immune modulation and tumor microenvironment interactions in non-small cell lung cancer (NSCLC). Elevated expression of PSG6 has been associated with poor prognosis, potentially due to its role in promoting tumor immune evasion and metastasis. Understanding PSG6 levels in NSCLC patients may help stratify risk and guide therapeutic decisions, influencing overall survival outcomes.",
  "ZCCHC4": "ZCCHC4 is a gene that encodes a zinc finger CCHC-type containing protein, which has been implicated in various cellular processes, including RNA metabolism and gene regulation. In the context of non-small cell lung cancer (NSCLC), alterations in ZCCHC4 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of ZCCHC4 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "GAS6": "GAS6 (Growth Arrest-Specific 6) is a gene that encodes a protein involved in cell survival, proliferation, and immune regulation, playing a role in the GAS6-AXL signaling pathway. In the context of non-small cell lung cancer (NSCLC), elevated GAS6 expression has been associated with poor prognosis, as it may promote tumor growth and metastasis while contributing to immune evasion. Consequently, high levels of GAS6 could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "DSTNP2": "DSTNP2 (Dystonin, also known as BPAG1) is a gene that encodes a cytoskeletal protein involved in maintaining cellular integrity and signaling. In the context of non-small cell lung cancer (NSCLC), alterations in DSTNP2 expression have been associated with tumor progression and metastasis, potentially serving as a prognostic marker. Elevated levels of DSTNP2 may correlate with poorer survival outcomes, influencing treatment decisions and highlighting the need for further investigation into its role in NSCLC therapeutic strategies.",
  "PDE11A": "PDE11A (phosphodiesterase 11A) is a gene that encodes an enzyme involved in the degradation of cyclic nucleotides, which play a crucial role in cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), altered expression of PDE11A has been associated with tumor progression and may influence the efficacy of certain therapies, such as those targeting the cAMP signaling pathway. Elevated PDE11A levels have been linked to poorer survival outcomes, suggesting that it could serve as a potential prognostic biomarker for NSCLC patients.",
  "FCGR3B": "FCGR3B (Fc gamma receptor IIIb) is a gene that encodes a receptor involved in the immune response, particularly in the binding of antibodies to immune cells. In the context of non-small cell lung cancer (NSCLC), variations in FCGR3B expression have been associated with differences in tumor immune microenvironment and response to immunotherapy, influencing prognosis. Higher expression levels of FCGR3B may correlate with improved survival outcomes, as they can enhance antibody-dependent cellular cytotoxicity against tumor cells, thereby potentially improving treatment efficacy and patient survival.",
  "ALDH4A1": "ALDH4A1 (Aldehyde Dehydrogenase 4 Family Member A1) is a gene involved in the metabolism of aldehydes and is implicated in cellular detoxification processes. In the context of non-small cell lung cancer (NSCLC), elevated expression of ALDH4A1 has been associated with poor prognosis, potentially due to its role in promoting tumor cell survival and resistance to chemotherapy. Consequently, high levels of ALDH4A1 may negatively influence patient survival outcomes by contributing to tumor aggressiveness and treatment resistance, making it a potential biomarker for stratifying NSCLC patients in clinical settings.",
  "MLXIP": "MLXIP (MLX interacting protein) is a gene that encodes a transcription factor involved in metabolic regulation and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), MLXIP has been implicated in tumor progression and may influence the sensitivity of cancer cells to therapies, potentially serving as a prognostic biomarker. Elevated expression levels of MLXIP have been associated with poorer survival outcomes, suggesting that it may play a critical role in the aggressiveness of NSCLC and the effectiveness of treatment strategies.",
  "HNRNPA3": "HNRNPA3 (Heterogeneous Nuclear Ribonucleoprotein A3) is a gene that encodes a protein involved in RNA processing and regulation, which has been implicated in various cancer pathways, including NSCLC. Its expression levels have been associated with tumor progression and patient prognosis, where higher HNRNPA3 expression may correlate with poorer survival outcomes due to its role in promoting cancer cell proliferation and metastasis. Understanding HNRNPA3's influence on NSCLC could aid in identifying high-risk patients and tailoring more effective treatment strategies.",
  "POLL": "POLL (Polymerase (DNA) lambda) is a gene involved in DNA repair processes, particularly in the context of base excision repair. In non-small cell lung cancer (NSCLC), alterations in POLL expression or function have been associated with tumor progression and resistance to certain therapies, potentially impacting patient prognosis. Elevated POLL activity may correlate with improved survival outcomes by enhancing genomic stability, while its dysregulation could lead to increased mutation rates and poorer survival.",
  "HHIPL2": "HHIPL2 (Hippocalcin-Like 2) is a gene that has been implicated in various cellular processes, including calcium signaling and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in HHIPL2 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of HHIPL2 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients based on their risk and guiding therapeutic decisions.",
  "ULK4": "ULK4 (Unc-51 Like Autophagy Activating Kinase 4) is a gene involved in the regulation of autophagy, a cellular process that can influence tumor growth and response to therapy. In the context of non-small cell lung cancer (NSCLC), altered expression of ULK4 has been associated with poor prognosis, potentially due to its role in promoting tumor cell survival and resistance to chemotherapy. Understanding ULK4's expression levels may help stratify patients based on survival outcomes and guide therapeutic decisions, particularly in the context of autophagy-modulating treatments.",
  "SLC16A1": "SLC16A1, also known as the monocarboxylate transporter 1 (MCT1), is a gene that encodes a protein involved in the transport of lactate and other monocarboxylates across cell membranes, playing a crucial role in cellular metabolism and tumor microenvironment adaptation. In non-small cell lung cancer (NSCLC), elevated expression of SLC16A1 has been associated with poor prognosis, as it may facilitate tumor growth and metastasis by enhancing the metabolic flexibility of cancer cells. Consequently, targeting SLC16A1 could potentially improve patient survival outcomes by disrupting the metabolic pathways that support tumor progression.",
  "IL15": "IL15 (Interleukin 15) is a cytokine that plays a crucial role in the immune response, particularly in the activation and proliferation of T cells and natural killer (NK) cells. In the context of non-small cell lung cancer (NSCLC), elevated IL15 expression has been associated with improved prognosis, as it may enhance anti-tumor immunity and promote a more effective immune response against cancer cells. Consequently, higher levels of IL15 could potentially correlate with better patient survival outcomes, making it a relevant biomarker for assessing treatment efficacy and guiding immunotherapeutic strategies.",
  "NAP1L2": "NAP1L2 (nucleosome assembly protein 1-like 2) is a gene involved in chromatin remodeling and gene expression regulation. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of NAP1L2 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Its role in modulating the tumor microenvironment and cell cycle progression may impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more tailored treatment approaches.",
  "RAI2": "RAI2 (Ribonucleic Acid Intron 2) is a gene that has been implicated in the regulation of cell proliferation and DNA repair mechanisms. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of RAI2 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Consequently, RAI2 expression may serve as a prognostic biomarker, helping to stratify patients based on survival outcomes and guiding treatment decisions.",
  "ECE1": "ECE1 (Endothelin-Converting Enzyme 1) is a gene involved in the processing of endothelin peptides, which play a role in tumor angiogenesis and progression in non-small cell lung cancer (NSCLC). Elevated expression levels of ECE1 have been associated with poor prognosis, as it may enhance tumor growth and metastasis through its effects on the tumor microenvironment. Consequently, targeting ECE1 could offer therapeutic potential, and its expression levels may serve as a biomarker for predicting patient survival outcomes in NSCLC.",
  "SLCO2B1": "SLCO2B1 is a gene encoding a member of the solute carrier family of transporters, specifically involved in the uptake of various endogenous compounds and drugs. In the context of non-small cell lung cancer (NSCLC), variations in SLCO2B1 expression have been associated with altered pharmacokinetics of chemotherapeutic agents, potentially impacting treatment efficacy and patient response. Consequently, SLCO2B1 polymorphisms may serve as prognostic biomarkers, influencing survival outcomes by affecting drug metabolism and overall treatment success in NSCLC patients.",
  "CTSL": "CTSL (cathepsin L) is a lysosomal cysteine protease gene that has been implicated in the progression and metastasis of non-small cell lung cancer (NSCLC). Elevated expression levels of CTSL have been associated with poor prognosis, as it may facilitate tumor invasion and immune evasion. Targeting CTSL could potentially improve treatment outcomes and survival rates in NSCLC patients by disrupting these pro-tumorigenic processes.",
  "EEF1G": "EEF1G (Eukaryotic Translation Elongation Factor 1 Gamma) is a gene that encodes a protein involved in the translation process, facilitating the elongation phase of protein synthesis. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of EEF1G have been associated with poor prognosis, as it may promote tumor growth and metastasis through enhanced protein synthesis and cellular proliferation. Consequently, high EEF1G expression could serve as a potential biomarker for reduced survival outcomes in NSCLC patients, influencing treatment decisions and prognostic assessments.",
  "CPN1": "CPN1 (Carboxypeptidase N) is a gene that encodes a protein involved in the regulation of immune responses and inflammation. In the context of non-small cell lung cancer (NSCLC), elevated levels of CPN1 have been associated with poor prognosis, potentially due to its role in promoting tumor growth and immune evasion. Understanding CPN1 expression may help stratify patients for targeted therapies and immunotherapies, ultimately influencing survival outcomes by identifying those at higher risk for aggressive disease.",
  "AKAP17A": "AKAP17A is a gene that encodes a protein involved in the regulation of protein kinase A (PKA) signaling pathways, which are crucial for various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of AKAP17A has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Elevated levels of AKAP17A may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "WAC": "WAC (Wnt Apical Compartment) is a gene that plays a role in the Wnt signaling pathway, which is crucial for cell proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), alterations in WAC expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated WAC levels may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients in clinical settings.",
  "SNHG14": "SNHG14 (Small Nucleolar RNA Host Gene 14) is a long non-coding RNA that has been implicated in the regulation of various cellular processes, including proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of SNHG14 have been associated with poor prognosis, as it may promote tumor growth and metastasis through the modulation of key signaling pathways. Consequently, high SNHG14 expression could serve as a potential biomarker for reduced survival outcomes in NSCLC patients, influencing treatment decisions and monitoring strategies.",
  "TBC1D2B": "TBC1D2B is a gene that encodes a protein involved in the regulation of intracellular trafficking and signaling pathways, which can influence tumor growth and metastasis in non-small cell lung cancer (NSCLC). Its expression levels have been associated with patient prognosis, where higher expression may correlate with poorer survival outcomes due to enhanced tumor aggressiveness. Understanding TBC1D2B's role could inform therapeutic strategies and risk stratification in NSCLC patients, potentially guiding treatment decisions and improving survival rates.",
  "TYRP1": "TYRP1 (tyrosinase-related protein 1) is a gene involved in melanin biosynthesis and is associated with pigmentation in melanoma; however, its expression has also been implicated in non-small cell lung cancer (NSCLC). Elevated levels of TYRP1 have been correlated with poor prognosis in NSCLC patients, potentially influencing tumor aggressiveness and response to therapies. Understanding TYRP1 expression may aid in stratifying patients for targeted treatments and improving survival outcomes through personalized therapeutic approaches.",
  "MYO1D": "MYO1D (Myosin ID) is a gene that encodes a motor protein involved in cellular processes such as cell motility and division. In the context of non-small cell lung cancer (NSCLC), MYO1D has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting MYO1D or its associated pathways could offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "CERS4": "CERS4 (Ceramide Synthase 4) is a gene involved in sphingolipid metabolism, which has been implicated in various cancer processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of CERS4 has been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of CERS4 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "GSTA2": "GSTA2 (Glutathione S-Transferase Alpha 2) is a gene encoding an enzyme involved in detoxification processes, particularly in the metabolism of chemotherapeutic agents and reactive oxygen species. In the context of non-small cell lung cancer (NSCLC), elevated expression of GSTA2 has been associated with resistance to chemotherapy and poorer prognosis, as it may contribute to the survival of cancer cells under oxidative stress. Consequently, GSTA2 expression levels could serve as a potential biomarker for predicting patient survival outcomes and tailoring treatment strategies in NSCLC.",
  "S100A11": "S100A11 is a gene that encodes a member of the S100 protein family, which is involved in various cellular processes, including cell proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of S100A11 have been associated with poor prognosis, as it may promote tumor growth and metastasis. Consequently, S100A11 expression could serve as a potential biomarker for survival outcomes, influencing treatment decisions and patient management strategies in NSCLC.",
  "PSMC6": "PSMC6 encodes a subunit of the 26S proteasome, which is involved in protein degradation and regulation of various cellular processes, including the cell cycle and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of PSMC6 has been associated with poor prognosis, as it may contribute to tumor progression and resistance to therapies. Elevated levels of PSMC6 can influence patient survival outcomes by promoting tumor cell survival and proliferation, thereby potentially leading to shorter overall survival in affected patients.",
  "HSF2BP": "HSF2BP (Heat Shock Factor 2 Binding Protein) is a gene implicated in the regulation of heat shock response and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), elevated expression of HSF2BP has been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Its role in modulating stress response pathways may impact patient survival outcomes by affecting tumor cell viability and response to treatment, making it a potential biomarker for stratifying NSCLC patients in clinical settings.",
  "NDN": "NDN (necdin) is a gene that encodes a protein involved in neuronal development and has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and poor prognosis, suggesting that NDN may play a role in tumor progression and resistance to therapy. Elevated NDN expression could potentially influence patient survival outcomes by promoting tumor growth and metastasis, making it a candidate for further investigation as a prognostic biomarker or therapeutic target in NSCLC.",
  "HIP1": "HIP1 (Huntingtin Interacting Protein 1) is a gene that encodes a protein involved in endocytosis and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), elevated expression of HIP1 has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Its role in modulating key oncogenic pathways may impact patient survival outcomes, making it a potential biomarker for stratifying risk and guiding therapeutic decisions.",
  "ASAP1": "ASAP1 (ArfGAP with SH3 domain, ankyrin repeat, and PH domain 1) is a gene that encodes a protein involved in cellular signaling and cytoskeletal dynamics, which has been implicated in cancer progression. In the context of non-small cell lung cancer (NSCLC), elevated expression of ASAP1 has been associated with poor prognosis, as it may promote tumor invasion and metastasis. Consequently, high levels of ASAP1 could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "CDCP1": "CDCP1 (CUB domain-containing protein 1) is a cell surface protein that has been implicated in the progression and metastasis of non-small cell lung cancer (NSCLC). Elevated expression of CDCP1 is associated with poor prognosis, as it may enhance tumor cell invasion and resistance to therapies, thereby negatively impacting patient survival outcomes. Targeting CDCP1 could offer a potential therapeutic strategy to improve treatment responses and overall survival in NSCLC patients.",
  "MATN3": "MATN3 (Matrilin 3) is a gene that encodes a protein involved in the extracellular matrix, playing a role in tissue structure and cellular interactions. In the context of non-small cell lung cancer (NSCLC), altered expression of MATN3 has been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated levels of MATN3 may correlate with poorer survival outcomes, influencing treatment decisions and patient management strategies in NSCLC.",
  "RPL26L1": "RPL26L1 is a gene encoding a ribosomal protein that plays a crucial role in protein synthesis and cellular growth. In the context of non-small cell lung cancer (NSCLC), altered expression of RPL26L1 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of treatments such as chemotherapy. Elevated levels of RPL26L1 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients based on their risk and treatment response.",
  "B3GALT2": "B3GALT2 is a gene encoding a beta-1,3-galactosyltransferase involved in glycosylation processes, which can influence tumor biology in non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker; higher expression may correlate with poorer survival outcomes. Understanding B3GALT2's role in NSCLC could inform therapeutic strategies, particularly in targeting glycosylation pathways to improve patient survival.",
  "CCR6": "CCR6 (C-C chemokine receptor type 6) is a gene that encodes a receptor involved in immune cell trafficking, particularly for T-helper 17 (Th17) cells, which play a role in inflammation and tumor immunity. In the context of non-small cell lung cancer (NSCLC), elevated CCR6 expression has been associated with poor prognosis, as it may facilitate tumor progression and metastasis by promoting an immunosuppressive microenvironment. Consequently, targeting CCR6 could potentially enhance therapeutic responses and improve survival outcomes in NSCLC patients by reactivating anti-tumor immunity.",
  "KLHL36": "KLHL36 is a gene that encodes a protein involved in the regulation of cellular processes, including protein degradation and stress response. In the context of non-small cell lung cancer (NSCLC), alterations in KLHL36 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated KLHL36 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "EGLN2": "EGLN2 (Egl-9 Family Hypoxia-Inducible Factor 2) is a gene that encodes a prolyl hydroxylase involved in the cellular response to hypoxia, playing a critical role in regulating the hypoxia-inducible factor (HIF) pathway. In the context of non-small cell lung cancer (NSCLC), elevated EGLN2 expression has been associated with poor prognosis, as it may promote tumor growth and metastasis under low oxygen conditions. Consequently, variations in EGLN2 expression levels can influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "ZNF835": "ZNF835 is a gene that encodes a zinc finger protein, which is implicated in transcriptional regulation and may play a role in tumorigenesis. In the context of non-small cell lung cancer (NSCLC), alterations in ZNF835 expression have been associated with poor prognosis, potentially influencing tumor growth and metastasis. Understanding its role could aid in stratifying patients for targeted therapies and improving survival outcomes through personalized treatment approaches.",
  "NSUN3": "NSUN3 is a gene encoding a methyltransferase involved in the modification of mitochondrial tRNA, which plays a critical role in mitochondrial function and cellular metabolism. In the context of non-small cell lung cancer (NSCLC), altered expression of NSUN3 has been associated with poor prognosis, potentially influencing tumor growth and resistance to therapies. Its impact on patient survival outcomes may be mediated through its effects on mitochondrial dynamics and energy metabolism, making it a potential biomarker for stratifying NSCLC patients for targeted therapies.",
  "GNLY": "GNLY (granulysin) is a gene that encodes a cytolytic protein involved in the immune response, particularly in the activation of T cells and natural killer (NK) cells. In the context of non-small cell lung cancer (NSCLC), elevated expression of GNLY has been associated with improved prognosis, as it may enhance anti-tumor immunity and contribute to tumor cell apoptosis. Consequently, higher levels of GNLY could correlate with better patient survival outcomes, making it a potential biomarker for assessing treatment efficacy and guiding immunotherapy strategies.",
  "EGLN1": "EGLN1 (Egl-9 Family Hypoxia-Inducible Factor 1) is a gene that encodes a prolyl hydroxylase involved in the cellular response to hypoxia, playing a critical role in the regulation of hypoxia-inducible factors (HIFs). In non-small cell lung cancer (NSCLC), elevated EGLN1 expression has been associated with poor prognosis, as it may promote tumor growth and metastasis under low oxygen conditions. Consequently, targeting EGLN1 or its downstream pathways could potentially improve patient survival outcomes by enhancing the efficacy of existing therapies and reducing tumor aggressiveness.",
  "ZBTB39": "ZBTB39, also known as ZNF750, is a gene that encodes a zinc finger transcription factor involved in regulating cellular differentiation and proliferation. In the context of non-small cell lung cancer (NSCLC), ZBTB39 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with patient prognosis. Higher expression of ZBTB39 has been associated with poorer survival outcomes, potentially influencing treatment strategies and highlighting its role as a prognostic biomarker in NSCLC.",
  "HGSNAT": "HGSNAT (Heparanase Glucuronidase N-Acetyltransferase) is a gene involved in the metabolism of heparan sulfate, which plays a role in tumor microenvironment modulation and cell signaling. In the context of non-small cell lung cancer (NSCLC), altered expression of HGSNAT has been associated with tumor aggressiveness and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Elevated levels of HGSNAT may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "VEGFA": "VEGFA (Vascular Endothelial Growth Factor A) is a gene that encodes a key protein involved in angiogenesis, the formation of new blood vessels, which is critical for tumor growth and metastasis in non-small cell lung cancer (NSCLC). Elevated levels of VEGFA have been associated with poor prognosis, as they can promote tumor vascularization and facilitate cancer progression, making it a potential target for anti-angiogenic therapies. Consequently, high VEGFA expression may correlate with reduced patient survival outcomes, highlighting its importance in both prognostic assessments and therapeutic strategies in NSCLC management.",
  "ZFP37": "ZFP37 is a zinc finger protein gene that has been implicated in the regulation of gene expression and cellular processes in non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and patient prognosis, where higher ZFP37 expression may correlate with poorer survival outcomes due to its potential role in promoting tumor aggressiveness and resistance to therapy. Understanding ZFP37's influence on NSCLC could provide insights into patient stratification and the development of targeted therapies, ultimately impacting survival rates.",
  "CEP131": "CEP131 is a gene that encodes a protein involved in cilia formation and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), alterations in CEP131 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of CEP131 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "ANO10": "ANO10 (anoctamin 10) is a gene that encodes a calcium-activated chloride channel, which has been implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in ANO10 expression have been associated with tumor progression and poor prognosis, suggesting its potential role as a biomarker for survival outcomes. Elevated ANO10 levels may influence patient survival by promoting aggressive tumor behavior, thereby impacting treatment responses and overall clinical outcomes.",
  "LTBP3": "LTBP3 (Latent Transforming Growth Factor Beta Binding Protein 3) is a gene involved in the regulation of TGF-\u03b2 signaling, which plays a critical role in tumor microenvironment modulation and extracellular matrix remodeling. In the context of non-small cell lung cancer (NSCLC), elevated LTBP3 expression has been associated with poor prognosis, as it may promote tumor progression and metastasis. Consequently, LTBP3 levels could serve as a potential biomarker for survival outcomes, influencing treatment strategies and patient management in NSCLC.",
  "PIAS4": "PIAS4 (Protein Inhibitor of Activated STAT4) is a gene that encodes a protein involved in the regulation of the STAT signaling pathway, which plays a critical role in immune response and tumor progression. In the context of non-small cell lung cancer (NSCLC), elevated expression of PIAS4 has been associated with poor prognosis, potentially due to its role in promoting tumor cell survival and immune evasion. Understanding PIAS4's influence on patient survival outcomes may provide insights into targeted therapies and immunotherapeutic strategies for NSCLC patients.",
  "NUAK2": "NUAK2 is a serine/threonine kinase gene that plays a role in cellular energy homeostasis and has been implicated in various cancer pathways, including those regulating cell proliferation and survival. In the context of non-small cell lung cancer (NSCLC), elevated expression of NUAK2 has been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Its role in modulating key signaling pathways may impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "CCDC121": "CCDC121 (Coiled-Coil Domain Containing 121) is a gene implicated in cellular processes such as cilia formation and signaling pathways. In the context of non-small cell lung cancer (NSCLC), alterations in CCDC121 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of CCDC121 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and therapeutic options.",
  "PLGRKT": "PLGRKT (also known as PLGRKT1) is a gene that encodes a protein involved in cellular signaling pathways, particularly those related to inflammation and immune response. In the context of non-small cell lung cancer (NSCLC), alterations in PLGRKT expression have been associated with tumor progression and may influence the efficacy of immunotherapies. Elevated levels of PLGRKT may correlate with poorer survival outcomes, suggesting its potential as a prognostic biomarker and a target for therapeutic intervention in NSCLC patients.",
  "TMSB10": "TMSB10 (Thymosin Beta 10) is a gene that encodes a protein involved in actin regulation and cellular motility, which has been implicated in tumor progression and metastasis in non-small cell lung cancer (NSCLC). Elevated expression levels of TMSB10 have been associated with poor prognosis, as it may enhance cancer cell invasiveness and resistance to therapy. Consequently, TMSB10 expression could serve as a potential biomarker for predicting survival outcomes in NSCLC patients, guiding treatment decisions and monitoring disease progression.",
  "GOT1": "GOT1 (Glutamate Oxidase 1) is a gene involved in amino acid metabolism and is implicated in the metabolic reprogramming of cancer cells, including non-small cell lung cancer (NSCLC). Elevated expression of GOT1 has been associated with poor prognosis in NSCLC patients, as it may contribute to tumor growth and resistance to therapy by enhancing the availability of metabolic substrates. Targeting GOT1 could potentially improve survival outcomes by disrupting the metabolic pathways that support tumor progression and treatment resistance.",
  "LDHC": "LDHC (lactate dehydrogenase C) is a gene that encodes an enzyme involved in the conversion of pyruvate to lactate, playing a crucial role in cellular metabolism and the Warburg effect, which is often upregulated in cancer cells, including non-small cell lung cancer (NSCLC). Elevated LDHC expression has been associated with poor prognosis in NSCLC, as it may promote tumor growth and metastasis by facilitating anaerobic glycolysis, leading to increased lactate production and an acidic tumor microenvironment. Consequently, high LDHC levels may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying risk and guiding therapeutic decisions in NSCLC management.",
  "STXBP1": "STXBP1 (Syntaxin Binding Protein 1) is a gene involved in synaptic vesicle trafficking and exocytosis, which has been implicated in various cellular processes, including those relevant to cancer biology. In the context of non-small cell lung cancer (NSCLC), alterations in STXBP1 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated STXBP1 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "FPGS": "FPGS (folylpolyglutamate synthetase) is a gene involved in folate metabolism, playing a crucial role in the synthesis of polyglutamated forms of folate, which are essential for DNA synthesis and repair. In the context of non-small cell lung cancer (NSCLC), altered expression of FPGS has been associated with the efficacy of antifolate chemotherapy agents, such as pemetrexed, and may serve as a prognostic biomarker for treatment response. Higher FPGS expression levels could potentially correlate with improved survival outcomes in NSCLC patients receiving folate-targeted therapies, highlighting its significance in personalized treatment strategies.",
  "GLTP": "GLTP (glycolipid transfer protein) is a gene that encodes a protein involved in lipid metabolism and membrane trafficking, which has been implicated in various cancer processes, including NSCLC. Its expression levels have been associated with tumor progression and metastasis, suggesting that GLTP may serve as a potential biomarker for prognosis in NSCLC patients. Elevated GLTP expression could correlate with poorer survival outcomes, influencing treatment decisions and highlighting the need for further investigation into its role in therapeutic resistance and disease management.",
  "CAVIN2": "CAVIN2 is a gene that encodes a protein involved in the formation and stability of caveolae, which are small invaginations in the cell membrane that play a role in various signaling pathways. In the context of non-small cell lung cancer (NSCLC), altered expression of CAVIN2 has been associated with tumor progression and metastasis, suggesting its potential as a prognostic biomarker. Higher levels of CAVIN2 expression may correlate with improved patient survival outcomes, possibly due to its involvement in modulating tumor microenvironment interactions and cellular signaling pathways critical for cancer development and response to therapy.",
  "ADGRL1": "ADGRL1 (Adhesion G Protein-Coupled Receptor L1) is a gene that encodes a receptor involved in cell adhesion and signaling pathways, which can influence tumor microenvironment interactions in non-small cell lung cancer (NSCLC). Elevated expression of ADGRL1 has been associated with poor prognosis, potentially due to its role in promoting tumor growth and metastasis. Understanding ADGRL1's impact on NSCLC may help identify patients at higher risk for aggressive disease and inform targeted therapeutic strategies, ultimately influencing survival outcomes.",
  "ZNF280D": "ZNF280D is a gene that encodes a zinc finger protein, which is involved in transcriptional regulation and may play a role in tumorigenesis. In the context of non-small cell lung cancer (NSCLC), alterations in ZNF280D expression have been associated with poor prognosis, potentially influencing tumor growth and metastasis. Elevated levels of ZNF280D may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "SNX10": "SNX10 (Sorting Nexin 10) is a gene involved in endosomal trafficking and cellular signaling pathways, which has been implicated in the regulation of tumor progression in non-small cell lung cancer (NSCLC). Elevated expression levels of SNX10 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Understanding SNX10's role in NSCLC may provide insights into patient survival outcomes and inform targeted treatment strategies.",
  "CALML3": "CALML3 (Calmodulin-like protein 3) is a gene that encodes a calcium-binding protein involved in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), CALML3 has been implicated in tumor progression and may serve as a prognostic biomarker; its expression levels have been associated with patient survival outcomes. Elevated CALML3 expression could indicate a more aggressive tumor phenotype, potentially influencing treatment decisions and overall survival in NSCLC patients.",
  "MRTFB": "MRTFB (myocardin-related transcription factor B) is a gene that encodes a transcription factor involved in regulating smooth muscle cell differentiation and cytoskeletal organization. In the context of non-small cell lung cancer (NSCLC), elevated MRTFB expression has been associated with poor prognosis, as it may promote tumor aggressiveness and metastasis. Consequently, high levels of MRTFB could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "TP53TG1": "TP53TG1 is a long non-coding RNA (lncRNA) that is associated with the TP53 tumor suppressor gene, playing a role in the regulation of cellular processes such as apoptosis and cell cycle control. In the context of non-small cell lung cancer (NSCLC), altered expression of TP53TG1 has been linked to poor prognosis, as it may contribute to tumor progression and resistance to therapies. Elevated levels of TP53TG1 expression could negatively influence patient survival outcomes by promoting aggressive tumor behavior and limiting the effectiveness of treatment strategies.",
  "IL6ST": "IL6ST (Interleukin 6 Signal Transducer) is a gene that encodes a protein involved in the IL-6 signaling pathway, which plays a critical role in inflammation and immune response. In the context of non-small cell lung cancer (NSCLC), elevated IL6ST expression has been associated with poor prognosis, as it may promote tumor growth and metastasis through its effects on the tumor microenvironment and immune evasion. Consequently, targeting IL6ST or its downstream signaling pathways could potentially improve patient survival outcomes by enhancing anti-tumor immunity and reducing tumor aggressiveness.",
  "ADTRP": "ADTRP (Androgen-Dependent Receptor Transporter) is a gene implicated in the regulation of androgen signaling pathways, which have been associated with tumor progression in non-small cell lung cancer (NSCLC). Elevated expression of ADTRP has been linked to poor prognosis, potentially influencing tumor aggressiveness and response to therapies targeting androgen receptors. Understanding ADTRP's role may help stratify patients for more personalized treatment approaches, ultimately impacting survival outcomes in NSCLC.",
  "KLK6": "KLK6 (Kallikrein-related peptidase 6) is a serine protease gene that has been implicated in the progression and metastasis of non-small cell lung cancer (NSCLC). Elevated expression levels of KLK6 have been associated with poor prognosis, as it may promote tumor growth and invasion through the modulation of the tumor microenvironment and immune response. Consequently, KLK6 expression could serve as a potential biomarker for stratifying NSCLC patients based on survival outcomes and guiding therapeutic decisions.",
  "MAN2A2": "MAN2A2 is a gene encoding a mannosidase enzyme involved in glycoprotein processing, which has been implicated in various cancer-related pathways, including those affecting tumor growth and immune evasion. In the context of non-small cell lung cancer (NSCLC), alterations in MAN2A2 expression have been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of MAN2A2 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients for more personalized treatment approaches.",
  "KXD1": "KXD1 is a gene implicated in the regulation of cellular stress responses and has been associated with tumor progression in non-small cell lung cancer (NSCLC). Its expression levels may correlate with patient prognosis, as alterations in KXD1 have been linked to tumor aggressiveness and resistance to therapies, potentially influencing overall survival outcomes. Understanding KXD1's role could aid in stratifying patients for targeted therapies and improving personalized treatment approaches in NSCLC.",
  "CDC42BPA": "CDC42BPA (CDC42 Binding Protein Alpha) is a gene that encodes a protein involved in cytoskeletal organization and cell signaling pathways, which are critical for cancer cell migration and invasion. In the context of non-small cell lung cancer (NSCLC), elevated expression of CDC42BPA has been associated with poor prognosis, as it may enhance tumor aggressiveness and metastasis. Consequently, targeting CDC42BPA could potentially improve patient survival outcomes by inhibiting tumor progression and spread.",
  "NDUFA5": "NDUFA5 is a gene encoding a subunit of the mitochondrial NADH dehydrogenase complex, which plays a critical role in cellular energy metabolism. In the context of non-small cell lung cancer (NSCLC), altered expression of NDUFA5 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies targeting metabolic pathways. Elevated levels of NDUFA5 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "PDCD1LG2": "PDCD1LG2, also known as PD-L2, is a gene that encodes a ligand for the programmed cell death protein 1 (PD-1) receptor, playing a crucial role in immune checkpoint regulation. In the context of non-small cell lung cancer (NSCLC), PDCD1LG2 expression has been associated with tumor immune evasion and may serve as a biomarker for response to immune checkpoint inhibitors, such as anti-PD-1/PD-L1 therapies. Higher levels of PDCD1LG2 expression may correlate with improved survival outcomes in patients receiving immunotherapy, highlighting its potential as a prognostic indicator in NSCLC treatment strategies.",
  "PPARD": "PPARD (Peroxisome Proliferator-Activated Receptor Delta) is a gene that encodes a nuclear receptor involved in lipid metabolism and inflammation regulation. In the context of non-small cell lung cancer (NSCLC), PPARD has been implicated in tumor progression and response to therapies, with studies suggesting that its expression levels may correlate with patient prognosis and survival outcomes. Elevated PPARD expression has been associated with poorer survival rates, potentially influencing treatment strategies and highlighting its role as a biomarker for therapeutic targeting in NSCLC.",
  "CRTAM": "CRTAM (Cytotoxic T-lymphocyte-associated protein 4 Receptor) is a gene that encodes a protein involved in immune regulation, particularly in T-cell activation and function. In the context of non-small cell lung cancer (NSCLC), CRTAM has been associated with tumor immune evasion and may serve as a biomarker for prognosis, as its expression levels can influence the effectiveness of immunotherapies. Higher CRTAM expression has been linked to poorer survival outcomes, suggesting that targeting this pathway could enhance therapeutic strategies and improve patient survival in NSCLC.",
  "KIF1C": "KIF1C (Kinesin Family Member 1C) is a gene that encodes a motor protein involved in intracellular transport, which has been implicated in various cancer processes, including cell proliferation and metastasis. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of KIF1C have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Consequently, KIF1C may serve as a prognostic biomarker, where its expression levels could help stratify patients based on survival outcomes and guide treatment decisions.",
  "EDNRB": "EDNRB (Endothelin Receptor Type B) is a gene that encodes a receptor involved in the endothelin signaling pathway, which plays a role in tumor progression and angiogenesis in non-small cell lung cancer (NSCLC). Elevated expression of EDNRB has been associated with poor prognosis and may influence treatment responses, particularly to therapies targeting the tumor microenvironment. Its modulation could potentially impact patient survival outcomes by affecting tumor growth and metastasis, making it a relevant biomarker for stratifying NSCLC patients in clinical settings.",
  "ACOT8": "ACOT8 (Acyl-CoA Thioesterase 8) is a gene involved in lipid metabolism, specifically in the hydrolysis of acyl-CoA thioesters, which can influence cellular energy homeostasis and signaling pathways. In the context of non-small cell lung cancer (NSCLC), altered expression of ACOT8 has been associated with tumor progression and may serve as a prognostic biomarker, potentially impacting treatment responses to therapies targeting metabolic pathways. Elevated ACOT8 levels could correlate with poorer survival outcomes, suggesting its role in tumor aggressiveness and the metabolic adaptation of cancer cells.",
  "GAPDH": "GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) is a housekeeping gene that plays a critical role in glycolysis and cellular metabolism. In the context of non-small cell lung cancer (NSCLC), elevated GAPDH expression has been associated with tumor progression and poor prognosis, potentially influencing cancer cell proliferation and survival. Its expression levels may serve as a biomarker for patient survival outcomes, with higher levels correlating with reduced overall survival, thereby providing insights for therapeutic targeting and patient stratification.",
  "OAZ2": "OAZ2 (ornithine decarboxylase antizyme 2) is a gene involved in polyamine metabolism, which has been implicated in tumor growth and progression in non-small cell lung cancer (NSCLC). Elevated expression levels of OAZ2 have been associated with poor prognosis, as it may promote cancer cell proliferation and resistance to apoptosis. Consequently, OAZ2 expression could serve as a potential biomarker for survival outcomes in NSCLC patients, influencing treatment strategies and prognostic assessments.",
  "NEBL": "NEBL (nebulin-like protein) is a gene that encodes a protein involved in cytoskeletal organization and cellular signaling. In the context of non-small cell lung cancer (NSCLC), altered expression of NEBL has been associated with tumor progression and metastasis, suggesting its potential role as a prognostic biomarker. Elevated NEBL levels may correlate with poorer survival outcomes, influencing treatment decisions and patient management strategies in NSCLC.",
  "LPAR4": "LPAR4 (Lysophosphatidic Acid Receptor 4) is a G protein-coupled receptor that plays a role in cell proliferation, survival, and migration, which are critical processes in the progression of non-small cell lung cancer (NSCLC). Elevated expression of LPAR4 has been associated with poor prognosis in NSCLC patients, potentially influencing tumor aggressiveness and response to therapies. Targeting LPAR4 may offer therapeutic opportunities to improve survival outcomes by modulating tumor microenvironment interactions and enhancing treatment efficacy.",
  "EPHB4": "EPHB4 is a gene that encodes a member of the ephrin receptor family, which plays a crucial role in cell signaling and tumor microenvironment interactions. In the context of non-small cell lung cancer (NSCLC), EPHB4 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting EPHB4 signaling pathways could offer potential therapeutic strategies, influencing patient survival by altering tumor behavior and enhancing treatment responses.",
  "ZFR2": "ZFR2 (Zinc Finger RNA Binding Protein 2) is a gene implicated in RNA processing and regulation, which has been associated with tumor progression in non-small cell lung cancer (NSCLC). Elevated expression levels of ZFR2 have been linked to poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Understanding ZFR2's role in NSCLC may aid in stratifying patients for targeted treatments and improving survival outcomes through personalized therapeutic approaches.",
  "SLC11A2": "SLC11A2 (solute carrier family 11 member 2) is a gene that encodes a protein involved in iron transport and homeostasis, which has been implicated in the progression of non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and patient prognosis, as altered iron metabolism can influence cancer cell proliferation and survival. High SLC11A2 expression may correlate with poorer survival outcomes in NSCLC patients, potentially serving as a biomarker for stratifying risk and guiding treatment decisions.",
  "OLFM4": "OLFM4 (Olfactory Marker Protein 4) is a gene that has been implicated in various cancers, including non-small cell lung cancer (NSCLC). It is associated with tumor progression and has been shown to play a role in immune evasion and tumor microenvironment modulation. Elevated expression levels of OLFM4 in NSCLC have been correlated with poor prognosis, suggesting that it may serve as a potential biomarker for survival outcomes and could influence treatment strategies targeting tumor-immune interactions.",
  "APBB1": "APBB1 (Amyloid Precursor Protein Binding Protein 1) is a gene that encodes a protein involved in intracellular signaling and may play a role in the regulation of cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of APBB1 has been associated with tumor progression and poor prognosis, potentially influencing the effectiveness of targeted therapies. Elevated levels of APBB1 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "SLC16A3": "SLC16A3, also known as MCT4, is a gene encoding a monocarboxylate transporter that plays a crucial role in lactate transport and metabolic regulation in tumor cells. In the context of non-small cell lung cancer (NSCLC), elevated expression of SLC16A3 has been associated with poor prognosis, as it facilitates the adaptation of cancer cells to hypoxic conditions and promotes tumor aggressiveness. Consequently, high levels of SLC16A3 may negatively influence patient survival outcomes by enhancing tumor growth and metastasis, making it a potential therapeutic target for improving NSCLC treatment strategies.",
  "MMP8": "MMP8 (Matrix Metalloproteinase 8) is a gene encoding an enzyme involved in the degradation of extracellular matrix components, playing a crucial role in tumor invasion and metastasis in non-small cell lung cancer (NSCLC). Elevated MMP8 expression has been associated with poor prognosis, as it may facilitate tumor progression and resistance to therapies. Consequently, MMP8 levels could serve as a potential biomarker for survival outcomes, guiding treatment decisions and prognostic assessments in NSCLC patients.",
  "ARHGAP44": "ARHGAP44 is a gene that encodes a Rho GTPase-activating protein, which plays a role in regulating cell migration and invasion. In the context of non-small cell lung cancer (NSCLC), altered expression of ARHGAP44 has been associated with tumor progression and poor prognosis, potentially influencing patient survival outcomes by affecting metastatic potential and response to targeted therapies. Understanding its role may help identify patients at higher risk and guide therapeutic strategies.",
  "PAFAH1B1": "PAFAH1B1, also known as platelet-activating factor acetylhydrolase 1b regulatory subunit 1, is a gene that encodes a protein involved in lipid metabolism and inflammatory responses. In the context of non-small cell lung cancer (NSCLC), alterations in PAFAH1B1 expression have been associated with tumor progression and poor prognosis, potentially influencing pathways related to cell proliferation and apoptosis. Elevated levels of PAFAH1B1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying risk and guiding therapeutic decisions in NSCLC management.",
  "KNL1": "KNL1 (Kinetochore Protein 1) is a gene that encodes a protein essential for proper chromosome segregation during cell division. In the context of non-small cell lung cancer (NSCLC), aberrant expression of KNL1 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of KNL1 may correlate with increased tumor aggressiveness, thereby negatively impacting patient survival outcomes.",
  "SLC35E3": "SLC35E3 is a gene encoding a nucleotide sugar transporter that has been implicated in various cellular processes, including glycosylation, which can affect tumor biology. In the context of non-small cell lung cancer (NSCLC), altered expression of SLC35E3 has been associated with poor prognosis and may influence tumor aggressiveness and response to therapies. Its role in modulating the tumor microenvironment and immune response suggests that SLC35E3 expression levels could serve as a potential biomarker for predicting patient survival outcomes and tailoring treatment strategies.",
  "ELAVL3": "ELAVL3 (embryonic lethal abnormal vision-like 3) is an RNA-binding protein that plays a critical role in post-transcriptional regulation of gene expression. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of ELAVL3 have been associated with poor prognosis, as it may promote tumor growth and metastasis by stabilizing oncogenic mRNAs. Consequently, high ELAVL3 expression could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "NEIL3": "NEIL3 (Nei-like DNA glycosylase 3) is a gene involved in the base excision repair pathway, which plays a critical role in maintaining genomic stability. In the context of non-small cell lung cancer (NSCLC), altered expression of NEIL3 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of DNA-damaging therapies. Elevated NEIL3 levels may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "STC2": "STC2 (Stanniocalcin 2) is a gene that encodes a glycoprotein involved in various cellular processes, including calcium homeostasis and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), elevated STC2 expression has been associated with poor prognosis, as it may promote tumor growth, metastasis, and resistance to chemotherapy. Consequently, STC2 levels could serve as a potential biomarker for stratifying patient survival outcomes and guiding therapeutic decisions in NSCLC management.",
  "PRSS8": "PRSS8, also known as prostasin, is a serine protease gene that has been implicated in various biological processes, including cell adhesion and invasion. In the context of non-small cell lung cancer (NSCLC), altered expression of PRSS8 has been associated with tumor progression and poor prognosis, suggesting its potential role as a biomarker for survival outcomes. Elevated levels of PRSS8 may influence patient survival by promoting aggressive tumor behavior, thereby impacting treatment responses and overall clinical outcomes.",
  "AVL9": "AVL9, also known as \"A Virus-Like Protein 9,\" is a gene that has been implicated in the regulation of immune responses and cellular stress pathways. In the context of non-small cell lung cancer (NSCLC), AVL9 expression levels have been associated with tumor progression and patient prognosis, where higher expression may correlate with poorer survival outcomes due to its potential role in promoting tumor immune evasion. Understanding AVL9's influence on tumor biology could inform treatment strategies, particularly in the development of immunotherapies aimed at enhancing anti-tumor immunity in NSCLC patients.",
  "GSTA4": "GSTA4 (Glutathione S-Transferase A4) is a gene that encodes an enzyme involved in the detoxification of reactive oxygen species and xenobiotics, playing a critical role in cellular defense mechanisms. In the context of non-small cell lung cancer (NSCLC), elevated expression of GSTA4 has been associated with poor prognosis, as it may contribute to chemotherapy resistance and tumor progression. Consequently, GSTA4 expression levels could serve as a potential biomarker for predicting patient survival outcomes and tailoring treatment strategies in NSCLC.",
  "ZNF205-AS1": "ZNF205-AS1 is a long non-coding RNA (lncRNA) that has been implicated in the regulation of gene expression and cellular processes in non-small cell lung cancer (NSCLC). Its overexpression has been associated with poor prognosis, potentially influencing tumor progression and metastasis. By modulating key signaling pathways, ZNF205-AS1 may serve as a prognostic biomarker, with higher levels correlating with decreased patient survival outcomes, thereby offering insights for targeted therapeutic strategies in NSCLC management.",
  "NFRKB": "NFRKB (Nuclear Factor Kappa B Subunit 1) is a gene that encodes a protein involved in the NF-\u03baB signaling pathway, which plays a critical role in regulating immune responses, inflammation, and cell survival. In the context of non-small cell lung cancer (NSCLC), aberrant activation of NFRKB has been associated with tumor progression, resistance to chemotherapy, and poor prognosis. Elevated expression levels of NFRKB may correlate with decreased patient survival outcomes, highlighting its potential as a therapeutic target and prognostic biomarker in NSCLC management.",
  "ADAM22": "ADAM22 is a gene encoding a member of the ADAM (A Disintegrin and Metalloproteinase) family, which is involved in cell adhesion and signaling processes. In the context of non-small cell lung cancer (NSCLC), ADAM22 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting ADAM22 or its associated pathways could offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "EP300": "EP300 (E1A binding protein p300) is a gene that encodes a transcriptional co-activator involved in various cellular processes, including cell growth and differentiation. In the context of non-small cell lung cancer (NSCLC), EP300 has been implicated in tumor progression and is associated with poor prognosis, as its dysregulation can affect key signaling pathways involved in cancer cell proliferation and survival. Elevated expression levels of EP300 may correlate with reduced patient survival outcomes, highlighting its potential as a therapeutic target and prognostic biomarker in NSCLC management.",
  "ZPBP": "ZPBP (Zonula Occludens Protein Binding Protein) is a gene that has been implicated in the regulation of cell adhesion and tight junction integrity, which are critical in tumor progression and metastasis in non-small cell lung cancer (NSCLC). Alterations in ZPBP expression have been associated with poor prognosis, as they may contribute to enhanced tumor invasiveness and resistance to therapies. Consequently, ZPBP expression levels could serve as a potential biomarker for predicting survival outcomes in NSCLC patients, guiding treatment decisions and monitoring disease progression.",
  "HNRNPH3": "HNRNPH3 (Heterogeneous Nuclear Ribonucleoprotein H3) is a gene involved in RNA processing and regulation, which has been implicated in the progression of non-small cell lung cancer (NSCLC). Elevated expression levels of HNRNPH3 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Its role in modulating key pathways related to cell proliferation and apoptosis may significantly impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for tailored treatment approaches.",
  "SLC1A2": "SLC1A2 (Solute Carrier Family 1 Member 2) is a gene encoding a high-affinity glutamate transporter, which plays a crucial role in regulating glutamate levels in the tumor microenvironment. In non-small cell lung cancer (NSCLC), altered expression of SLC1A2 has been associated with tumor growth, metastasis, and resistance to therapies, suggesting its potential as a prognostic biomarker. Elevated SLC1A2 expression may correlate with poorer survival outcomes, highlighting its relevance in guiding treatment strategies and patient management in NSCLC.",
  "RNASEH1": "RNASEH1 is a gene encoding ribonuclease H1, an enzyme involved in RNA metabolism and DNA replication. In the context of non-small cell lung cancer (NSCLC), alterations in RNASEH1 expression have been associated with tumor progression and may influence the efficacy of certain therapies, such as those targeting DNA repair mechanisms. Elevated RNASEH1 levels could correlate with poorer survival outcomes, highlighting its potential as a prognostic biomarker and a therapeutic target in NSCLC management.",
  "TH": "The feature \"TH\" refers to the gene encoding tyrosine hydroxylase, an enzyme involved in catecholamine synthesis. In the context of non-small cell lung cancer (NSCLC), elevated expression of TH has been associated with tumor progression and poor prognosis, potentially influencing the tumor microenvironment and stress response pathways. Its role in modulating neuroendocrine signaling may impact patient survival outcomes, suggesting that TH could serve as a biomarker for aggressive disease and a potential therapeutic target in NSCLC management.",
  "AKAP3": "AKAP3 (A-kinase anchoring protein 3) is a gene that encodes a protein involved in the regulation of protein kinase A (PKA) signaling pathways, which are critical for various cellular processes, including cell proliferation and survival. In the context of non-small cell lung cancer (NSCLC), altered expression of AKAP3 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapies. Elevated levels of AKAP3 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "GLRA3": "GLRA3 (Glycine Receptor Alpha 3) is a gene that encodes a subunit of the glycine receptor, which is involved in inhibitory neurotransmission in the central nervous system. In the context of non-small cell lung cancer (NSCLC), altered expression of GLRA3 has been associated with tumor progression and may influence the tumor microenvironment, potentially affecting patient prognosis. Higher levels of GLRA3 expression have been linked to poorer survival outcomes, suggesting that it could serve as a prognostic biomarker and a potential therapeutic target in NSCLC management.",
  "MFAP2": "MFAP2 (Microfibril-Associated Protein 2) is a gene that encodes a protein involved in the structural integrity of the extracellular matrix and is implicated in tumor microenvironment interactions. In the context of non-small cell lung cancer (NSCLC), elevated MFAP2 expression has been associated with poor prognosis, potentially influencing tumor progression and metastasis. Its role in modulating the tumor microenvironment may affect patient survival outcomes by promoting cancer cell invasion and resistance to therapies, making it a potential biomarker for stratifying NSCLC patients for more aggressive treatment approaches.",
  "BSG": "BSG (Basigin) is a gene that encodes a transmembrane glycoprotein involved in various cellular processes, including cell adhesion and immune response modulation. In the context of non-small cell lung cancer (NSCLC), BSG has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting BSG or its associated pathways could offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "NOCT": "NOCT (Nicotinamide N-methyltransferase) is a gene involved in the metabolism of nicotinamide, which plays a role in cellular energy homeostasis and stress response. In the context of non-small cell lung cancer (NSCLC), altered expression of NOCT has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies targeting metabolic pathways. Elevated NOCT levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "SOX2": "SOX2 is a transcription factor gene that plays a critical role in maintaining stem cell pluripotency and regulating cellular differentiation. In the context of non-small cell lung cancer (NSCLC), SOX2 overexpression has been associated with poor prognosis, as it is linked to tumor aggressiveness, metastasis, and resistance to therapies. Elevated SOX2 levels may negatively influence patient survival outcomes by promoting tumor growth and limiting the effectiveness of conventional treatments, making it a potential target for therapeutic intervention and a biomarker for stratifying patient risk.",
  "CTAGE9": "CTAGE9 (Cancer/Testis Antigen 9) is a gene that encodes a protein typically expressed in germ cells and is aberrantly expressed in various cancers, including non-small cell lung cancer (NSCLC). Its expression has been associated with poor prognosis in NSCLC patients, potentially serving as a biomarker for tumor aggressiveness and response to immunotherapy. Elevated levels of CTAGE9 may influence patient survival outcomes by indicating a more advanced disease state and a higher likelihood of metastasis, thereby guiding treatment decisions and monitoring strategies.",
  "BASP1": "BASP1 (Brain Abundant, Membrane Attached Protein 1) is a gene implicated in various cellular processes, including cell adhesion and signaling, which may influence tumor behavior in non-small cell lung cancer (NSCLC). Elevated expression of BASP1 has been associated with poor prognosis in NSCLC patients, potentially due to its role in promoting tumor invasiveness and metastasis. Understanding BASP1's expression levels could aid in stratifying patients for more personalized treatment approaches and improving survival outcomes through targeted therapies.",
  "AGTR1": "AGTR1 (Angiotensin II Receptor Type 1) is a gene that encodes a receptor involved in the renin-angiotensin system, which regulates blood pressure and fluid balance. In the context of non-small cell lung cancer (NSCLC), AGTR1 has been implicated in tumor progression and angiogenesis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting AGTR1 could offer therapeutic potential, as modulation of this pathway may influence tumor growth and metastasis, thereby impacting patient survival.",
  "PML": "PML (Promyelocytic Leukemia) is a tumor suppressor gene that plays a critical role in regulating apoptosis, cell cycle progression, and DNA damage response. In the context of non-small cell lung cancer (NSCLC), altered expression or mutations in PML have been associated with poor prognosis and resistance to chemotherapy, suggesting its potential as a biomarker for treatment response. Elevated PML levels may enhance sensitivity to certain therapies, thereby influencing patient survival outcomes by potentially improving treatment efficacy and overall survival rates.",
  "DAAM1": "DAAM1 (Dishevelled Associated Activator of Morphogenesis 1) is a gene involved in the Wnt signaling pathway, which plays a critical role in cell proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), elevated expression of DAAM1 has been associated with poor prognosis, as it may promote tumor growth and metastasis. Consequently, high levels of DAAM1 expression could serve as a potential biomarker for reduced survival outcomes in NSCLC patients, influencing treatment decisions and strategies aimed at targeting Wnt signaling.",
  "SSRP1": "SSRP1 (Structure Specific Recognition Protein 1) is a gene that encodes a protein involved in DNA repair and chromatin remodeling, playing a critical role in maintaining genomic stability. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of SSRP1 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. By modulating DNA repair mechanisms, SSRP1 may impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more personalized treatment approaches.",
  "RAP1GAP2": "RAP1GAP2 is a gene that encodes a GTPase-activating protein involved in the regulation of the RAP1 signaling pathway, which plays a role in cell adhesion and migration. In the context of non-small cell lung cancer (NSCLC), altered expression of RAP1GAP2 has been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated levels of RAP1GAP2 may correlate with improved survival outcomes, suggesting its potential utility in guiding treatment decisions and patient management strategies.",
  "SLC27A5": "SLC27A5 is a gene encoding a fatty acid transporter that plays a crucial role in lipid metabolism and cellular signaling. In the context of non-small cell lung cancer (NSCLC), altered expression of SLC27A5 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of therapies targeting metabolic pathways. Elevated levels of SLC27A5 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "HUNK": "HUNK (Hormonally Upregulated Neurological Kinase) is a gene that has been implicated in the regulation of cell proliferation and apoptosis, with emerging evidence suggesting its role in the progression of non-small cell lung cancer (NSCLC). Elevated expression levels of HUNK have been associated with poor prognosis in NSCLC patients, potentially influencing tumor aggressiveness and resistance to therapies. Understanding HUNK's role could aid in stratifying patients for targeted treatments and improving survival outcomes through personalized therapeutic approaches.",
  "SLC2A5": "SLC2A5, also known as GLUT5, is a gene encoding a fructose transporter that plays a role in cellular metabolism and energy homeostasis. In the context of non-small cell lung cancer (NSCLC), altered expression of SLC2A5 has been associated with tumor progression and poor prognosis, potentially influencing the metabolic adaptation of cancer cells. Elevated levels of SLC2A5 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for aggressive disease and a target for therapeutic intervention.",
  "ATP6V0A1": "ATP6V0A1 encodes a subunit of the vacuolar ATPase, which is involved in regulating intracellular pH and protein degradation pathways. In the context of non-small cell lung cancer (NSCLC), elevated expression of ATP6V0A1 has been associated with poor prognosis, as it may enhance tumor cell survival and resistance to chemotherapy by promoting autophagy and modulating the tumor microenvironment. Consequently, high levels of ATP6V0A1 could negatively influence patient survival outcomes, making it a potential biomarker for stratifying treatment approaches in NSCLC.",
  "GCH1": "GCH1 (GTP cyclohydrolase 1) is a gene involved in the biosynthesis of tetrahydrobiopterin, a cofactor critical for the production of neurotransmitters and nitric oxide. In the context of non-small cell lung cancer (NSCLC), elevated GCH1 expression has been associated with poor prognosis, potentially due to its role in promoting tumor growth and angiogenesis. Targeting GCH1 may influence patient survival outcomes by altering tumor metabolism and enhancing the efficacy of existing therapies, making it a potential biomarker for stratifying treatment approaches in NSCLC.",
  "SIGLEC9": "SIGLEC9 (Sialic Acid Binding Ig-like Lectin 9) is a gene that encodes a receptor involved in immune regulation, particularly in modulating the activity of immune cells in the tumor microenvironment. In the context of non-small cell lung cancer (NSCLC), elevated expression of SIGLEC9 has been associated with poor prognosis, as it may facilitate immune evasion by tumors, thereby influencing treatment responses and overall survival outcomes. Targeting SIGLEC9 or its pathways could potentially enhance anti-tumor immunity and improve survival rates in NSCLC patients.",
  "CBX4": "CBX4 (Chromobox 4) is a gene that encodes a protein involved in chromatin remodeling and gene regulation, playing a critical role in cellular processes such as proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), elevated expression of CBX4 has been associated with poor prognosis, as it may promote tumor growth and metastasis. Consequently, high levels of CBX4 could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "RPL28": "RPL28 is a ribosomal protein gene that plays a crucial role in protein synthesis and cellular growth. In the context of non-small cell lung cancer (NSCLC), altered expression of RPL28 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of treatments such as chemotherapy. Elevated levels of RPL28 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and treatment response.",
  "KCNJ6": "KCNJ6 encodes a potassium ion channel that is involved in regulating cellular excitability and signaling pathways. In the context of non-small cell lung cancer (NSCLC), alterations in KCNJ6 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of KCNJ6 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "PTPRZ1": "PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1) is a gene that encodes a receptor-type protein tyrosine phosphatase involved in cell signaling pathways that regulate cell growth and differentiation. In the context of non-small cell lung cancer (NSCLC), PTPRZ1 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting PTPRZ1 or its downstream signaling pathways could offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "NPY4R": "NPY4R (Neuropeptide Y receptor Y4) is a gene that encodes a receptor involved in neuropeptide signaling pathways, which have been implicated in tumor growth and metastasis in non-small cell lung cancer (NSCLC). Elevated expression of NPY4R has been associated with poor prognosis, potentially influencing tumor microenvironment interactions and resistance to therapies. Understanding NPY4R's role may help identify patients at higher risk for aggressive disease and inform treatment strategies, ultimately impacting survival outcomes.",
  "TTC28": "TTC28 (Tetratricopeptide Repeat Domain 28) is a gene that has been implicated in various cellular processes, including cell cycle regulation and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in TTC28 expression have been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Understanding TTC28's role may help identify patients at higher risk for adverse outcomes, guiding more personalized treatment strategies and improving survival predictions.",
  "GTF2H2": "GTF2H2 (General Transcription Factor IIH Subunit 2) is a gene involved in the transcriptional regulation and DNA repair processes, particularly in the nucleotide excision repair pathway. In the context of non-small cell lung cancer (NSCLC), alterations in GTF2H2 expression have been associated with tumor progression and resistance to certain therapies, potentially impacting patient prognosis. Elevated levels of GTF2H2 may correlate with poorer survival outcomes, suggesting its role as a potential biomarker for stratifying NSCLC patients based on treatment response and overall survival.",
  "KHSRP": "KHSRP (KH-type splicing regulatory protein) is a gene involved in RNA processing and regulation, which has been implicated in the progression of non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and patient prognosis, where higher KHSRP expression may correlate with poorer survival outcomes due to its role in promoting cancer cell proliferation and metastasis. Understanding KHSRP's influence on NSCLC could aid in identifying potential therapeutic targets and stratifying patients based on their risk profiles.",
  "FHIT": "FHIT (Fragile Histidine Triad) is a tumor suppressor gene that plays a critical role in the regulation of apoptosis and cell cycle control. In the context of non-small cell lung cancer (NSCLC), loss of FHIT expression has been associated with poor prognosis, as it may contribute to tumor progression and resistance to therapy. Consequently, alterations in FHIT expression can serve as a potential biomarker for survival outcomes, influencing treatment decisions and patient management strategies.",
  "REPIN1": "REPIN1 (recombination repair protein 1) is a gene involved in DNA repair mechanisms, particularly in the context of homologous recombination. In non-small cell lung cancer (NSCLC), altered expression of REPIN1 has been associated with poor prognosis, as it may contribute to genomic instability and resistance to therapies, including chemotherapy and targeted treatments. Elevated levels of REPIN1 could potentially influence patient survival outcomes by promoting tumor aggressiveness and reducing treatment efficacy, highlighting its relevance as a prognostic biomarker in NSCLC management.",
  "LAPTM5": "LAPTM5 (lysosomal protein transmembrane 5) is a gene that encodes a protein involved in lysosomal function and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), LAPTM5 has been implicated in tumor progression and resistance to chemotherapy, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. By influencing tumor microenvironment interactions and drug response, LAPTM5 could serve as a potential biomarker for stratifying NSCLC patients for tailored therapeutic approaches.",
  "R3HDM4": "R3HDM4 is a gene that encodes a protein involved in RNA metabolism and has been implicated in various cellular processes, including stress response and apoptosis. In the context of non-small cell lung cancer (NSCLC), alterations in R3HDM4 expression have been associated with tumor progression and may serve as a prognostic biomarker, influencing treatment responses to targeted therapies and immunotherapy. Elevated levels of R3HDM4 expression could correlate with poorer survival outcomes, highlighting its potential as a therapeutic target and a prognostic indicator in NSCLC management.",
  "SAMD9": "SAMD9 is a gene that encodes a protein involved in immune response and cellular stress pathways. In the context of non-small cell lung cancer (NSCLC), alterations in SAMD9 expression have been associated with poor prognosis, potentially influencing tumor progression and response to therapies. Elevated levels of SAMD9 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "PTPRG": "PTPRG (Protein Tyrosine Phosphatase Receptor Type G) is a gene that encodes a receptor-type protein tyrosine phosphatase, which is involved in regulating cell signaling pathways that affect cell growth and differentiation. In the context of non-small cell lung cancer (NSCLC), PTPRG has been associated with tumor suppressive functions, and its downregulation or loss of expression may correlate with poor prognosis and aggressive tumor behavior. Consequently, alterations in PTPRG expression could influence patient survival outcomes by impacting tumor progression and response to targeted therapies, making it a potential biomarker for stratifying NSCLC patients in clinical settings.",
  "ICOS": "ICOS (Inducible T-cell COStimulator) is a co-stimulatory molecule expressed on activated T cells, playing a crucial role in T cell activation and immune response regulation. In the context of non-small cell lung cancer (NSCLC), elevated ICOS expression has been associated with improved prognosis, as it may enhance anti-tumor immunity and response to immunotherapies, such as checkpoint inhibitors. Consequently, assessing ICOS levels could provide valuable insights into patient survival outcomes and guide treatment strategies in NSCLC.",
  "SIM1": "SIM1 (Single-minded family bHLH transcription factor 1) is a gene that encodes a transcription factor involved in neuroendocrine differentiation and tumor progression. In the context of non-small cell lung cancer (NSCLC), altered expression of SIM1 has been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of SIM1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "POLR2J4": "POLR2J4 encodes a subunit of RNA polymerase II, which is crucial for mRNA synthesis and gene expression regulation. In the context of non-small cell lung cancer (NSCLC), alterations in POLR2J4 expression have been associated with tumor progression and poor prognosis, potentially influencing the efficacy of targeted therapies and immunotherapy. Elevated levels of POLR2J4 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and treatment response.",
  "P2RX5": "P2RX5 is a gene encoding a purinergic receptor that plays a role in cellular signaling and inflammation. In the context of non-small cell lung cancer (NSCLC), P2RX5 has been implicated in tumor progression and immune response modulation, with studies suggesting that its expression levels may correlate with patient prognosis and treatment response. Elevated P2RX5 expression has been associated with poorer survival outcomes, potentially influencing therapeutic strategies and guiding personalized treatment approaches in NSCLC patients.",
  "SEPTIN10": "SEPTIN10 is a gene that encodes a member of the septin family of proteins, which are involved in cytoskeletal organization and cell division. In the context of non-small cell lung cancer (NSCLC), altered expression of SEPTIN10 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of SEPTIN10 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "UGT2A3": "UGT2A3 is a gene encoding a member of the UDP-glucuronosyltransferase family, which is involved in the metabolism of various endogenous and exogenous compounds, including drugs and carcinogens. In the context of non-small cell lung cancer (NSCLC), altered expression of UGT2A3 has been associated with variations in drug metabolism and response to chemotherapy, potentially influencing treatment efficacy and toxicity. Consequently, UGT2A3 expression levels may serve as a prognostic biomarker, with implications for patient survival outcomes by affecting therapeutic strategies and overall treatment response.",
  "VPS9D1": "VPS9D1 (VPS9 domain-containing protein 1) is a gene implicated in endosomal trafficking and cellular signaling pathways, which may influence tumor progression in non-small cell lung cancer (NSCLC). Its expression levels have been associated with patient prognosis, where higher VPS9D1 expression correlates with poor survival outcomes, potentially due to its role in promoting cancer cell proliferation and metastasis. Understanding VPS9D1's impact on NSCLC could inform therapeutic strategies and patient stratification for targeted treatments.",
  "LAMA4": "LAMA4 (Laminin Alpha 4) is a gene that encodes a protein component of the extracellular matrix, playing a crucial role in cell adhesion, migration, and tissue architecture. In the context of non-small cell lung cancer (NSCLC), LAMA4 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting LAMA4 or its associated pathways could offer potential therapeutic strategies to improve patient survival by inhibiting tumor growth and dissemination.",
  "TMEM185B": "TMEM185B is a gene that encodes a transmembrane protein, which has been implicated in various cellular processes, including cell signaling and proliferation. In the context of non-small cell lung cancer (NSCLC), alterations in TMEM185B expression have been associated with tumor aggressiveness and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of TMEM185B may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "DGKE": "DGKE (Diacylglycerol Kinase E) is a gene involved in lipid metabolism and signaling pathways, which has been implicated in the regulation of cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of DGKE has been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapies. Elevated levels of DGKE may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "TEX14": "TEX14 (Testis Expressed 14) is a gene that has been implicated in various cellular processes, including cell adhesion and migration, which are critical in cancer progression. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of TEX14 have been associated with poor prognosis, potentially influencing tumor aggressiveness and metastasis. Consequently, TEX14 may serve as a prognostic biomarker, where its expression levels could help stratify patients for more tailored therapeutic approaches and inform survival outcomes.",
  "ALDOA": "ALDOA (Aldolase A) is a gene that encodes an enzyme involved in glycolysis, playing a crucial role in cellular metabolism and energy production. In the context of non-small cell lung cancer (NSCLC), elevated ALDOA expression has been associated with poor prognosis, as it may promote tumor growth and metastasis through enhanced glycolytic activity. Consequently, high levels of ALDOA could negatively influence patient survival outcomes, making it a potential biomarker for stratifying risk and guiding therapeutic decisions in NSCLC management.",
  "SIRT5": "SIRT5 is a gene that encodes a member of the sirtuin family of proteins, which are involved in cellular metabolism and stress response. In the context of non-small cell lung cancer (NSCLC), SIRT5 has been implicated in tumor progression and metabolic reprogramming, influencing pathways such as oxidative stress and mitochondrial function. Elevated SIRT5 expression has been associated with poor prognosis in NSCLC patients, suggesting that it may serve as a potential biomarker for survival outcomes and a target for therapeutic intervention.",
  "PPFIBP2": "PPFIBP2 (Profilin-binding protein 2) is a gene implicated in cell adhesion and migration, which plays a role in tumor progression and metastasis in non-small cell lung cancer (NSCLC). Elevated expression levels of PPFIBP2 have been associated with poor prognosis, as it may enhance tumor invasiveness and resistance to therapies. Consequently, PPFIBP2 expression could serve as a potential biomarker for stratifying NSCLC patients based on survival outcomes and guiding treatment decisions.",
  "CDK4": "CDK4 (Cyclin-Dependent Kinase 4) is a key regulatory gene involved in the cell cycle, specifically in the transition from the G1 phase to the S phase. In non-small cell lung cancer (NSCLC), aberrations in CDK4, such as amplifications or mutations, have been associated with poor prognosis and may contribute to tumor proliferation and resistance to therapies. Targeting CDK4 with specific inhibitors has shown promise in improving survival outcomes, particularly in patients with CDK4 alterations, highlighting its potential as a therapeutic biomarker in NSCLC management.",
  "CTSV": "CTSV (cathepsin V) is a cysteine protease that has been implicated in the tumor microenvironment of non-small cell lung cancer (NSCLC). Its expression levels are associated with tumor aggressiveness and can influence the metastatic potential of cancer cells, thereby impacting prognosis. Elevated CTSV expression may correlate with poorer survival outcomes, making it a potential biomarker for stratifying patients and guiding therapeutic decisions in NSCLC management.",
  "TLL2": "TLL2 (Tolloid-like 2) is a gene that encodes a protein involved in the regulation of extracellular matrix components and has been implicated in tumor progression and metastasis. In the context of non-small cell lung cancer (NSCLC), altered expression of TLL2 has been associated with poor prognosis, potentially influencing tumor invasiveness and response to therapies. Elevated TLL2 levels may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more aggressive treatment approaches.",
  "ZNF654": "ZNF654 is a zinc finger protein gene that has been implicated in the regulation of gene expression and cellular processes in non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and patient prognosis, with higher ZNF654 expression correlating with poorer survival outcomes. Understanding ZNF654's role in NSCLC may provide insights into potential therapeutic targets and help stratify patients based on their risk profiles for more personalized treatment approaches.",
  "C1QB": "C1QB is a gene that encodes a component of the complement system, specifically involved in immune response regulation. In the context of non-small cell lung cancer (NSCLC), elevated expression of C1QB has been associated with a more favorable prognosis, potentially due to its role in enhancing anti-tumor immunity and modulating the tumor microenvironment. Understanding C1QB's influence on immune pathways may provide insights into patient survival outcomes and inform therapeutic strategies, particularly in immunotherapy approaches.",
  "NIBAN1": "NIBAN1 is a gene that encodes a protein involved in cellular processes such as apoptosis and cell signaling, which has been implicated in the progression of non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and patient prognosis, where higher NIBAN1 expression may correlate with poorer survival outcomes. Understanding NIBAN1's role could provide insights into potential therapeutic targets and help stratify patients based on their risk profiles in NSCLC management.",
  "CEP97": "CEP97 (Centrosomal Protein 97) is a gene that encodes a protein involved in the regulation of centrosome function and cell cycle progression. In the context of non-small cell lung cancer (NSCLC), altered expression of CEP97 has been associated with tumor aggressiveness and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of CEP97 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "DCLK1": "DCLK1 (Doublecortin-like kinase 1) is a gene that encodes a protein involved in neuronal development and has been implicated in cancer biology, particularly in non-small cell lung cancer (NSCLC). Elevated expression of DCLK1 has been associated with poor prognosis in NSCLC, as it may promote tumor growth and metastasis through its role in stem cell-like properties and epithelial-mesenchymal transition. Consequently, targeting DCLK1 could offer a novel therapeutic strategy, potentially improving survival outcomes for patients with aggressive NSCLC phenotypes.",
  "RPL13": "RPL13 is a gene encoding a ribosomal protein that plays a critical role in protein synthesis and cellular growth. In the context of non-small cell lung cancer (NSCLC), altered expression of RPL13 has been associated with tumor progression and poor prognosis, potentially influencing pathways related to cell proliferation and apoptosis. Elevated levels of RPL13 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "WT1": "WT1 (Wilms' Tumor 1) is a gene that encodes a transcription factor involved in cell growth and differentiation, and its expression has been implicated in various cancers, including non-small cell lung cancer (NSCLC). In NSCLC, elevated WT1 expression has been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Consequently, assessing WT1 levels may provide valuable prognostic information and guide treatment decisions, as targeting WT1 could enhance therapeutic efficacy and improve patient survival outcomes.",
  "OPTN": "OPTN (optineurin) is a gene that encodes a protein involved in various cellular processes, including autophagy and inflammation. In the context of non-small cell lung cancer (NSCLC), alterations in OPTN expression have been associated with tumor progression and poor prognosis, potentially influencing the efficacy of targeted therapies and immunotherapy. Elevated levels of OPTN may correlate with adverse survival outcomes, highlighting its potential as a biomarker for stratifying patient risk and guiding treatment decisions.",
  "WHRN": "WHRN (Whirlin) is a gene that encodes a protein involved in the regulation of cellular signaling pathways and has been implicated in the development and progression of non-small cell lung cancer (NSCLC). Alterations in WHRN expression have been associated with tumor aggressiveness and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Consequently, WHRN may serve as a prognostic biomarker, where its expression levels could help stratify patients based on survival outcomes and guide therapeutic decision-making.",
  "TTYH1": "TTYH1 (Ttyh1, also known as \"Ttyh1 gene\") is a gene that encodes a protein involved in cellular signaling and may play a role in tumor microenvironment interactions. In the context of non-small cell lung cancer (NSCLC), altered expression of TTYH1 has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Elevated levels of TTYH1 expression may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "DIAPH3": "DIAPH3 (Diaphanous-related formin 3) is a gene that encodes a protein involved in actin cytoskeleton dynamics and cellular signaling. In the context of non-small cell lung cancer (NSCLC), alterations in DIAPH3 expression have been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated levels of DIAPH3 may correlate with poorer survival outcomes, influencing treatment strategies and patient management by highlighting the need for targeted therapies that address its role in tumor biology.",
  "PPP1R3D": "PPP1R3D is a gene that encodes a regulatory subunit of protein phosphatase 1, which is involved in glycogen metabolism and cellular signaling pathways. In the context of non-small cell lung cancer (NSCLC), alterations in PPP1R3D expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of PPP1R3D may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and therapeutic options.",
  "TRNAU1AP": "TRNAU1AP (tRNA-derived RNA 1-activating protein) is a gene implicated in the regulation of tRNA metabolism and has been associated with various cancer types, including non-small cell lung cancer (NSCLC). Its overexpression has been linked to poor prognosis in NSCLC patients, potentially influencing tumor growth and metastasis through modulation of cellular stress responses and apoptosis. Consequently, TRNAU1AP may serve as a prognostic biomarker, with higher expression levels correlating with decreased survival outcomes, thereby offering insights for targeted therapeutic strategies.",
  "ZBTB22": "ZBTB22 is a gene that encodes a zinc finger transcription factor, which has been implicated in various cellular processes, including immune response and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of ZBTB22 has been associated with tumor progression and may serve as a prognostic biomarker, influencing patient survival outcomes by modulating tumor microenvironment interactions and immune evasion. Understanding its role could aid in stratifying patients for targeted therapies and improving treatment strategies.",
  "DNAJA1": "DNAJA1 is a gene that encodes a member of the DnaJ heat shock protein family, which plays a crucial role in protein folding and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), elevated expression of DNAJA1 has been associated with poor prognosis, potentially influencing tumor growth and resistance to therapies. Its role in modulating the tumor microenvironment and response to treatment may significantly impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients in clinical settings.",
  "AOX1": "AOX1 (Aldehyde Oxidase 1) is a gene that encodes an enzyme involved in the metabolism of aldehydes and is implicated in oxidative stress responses. In the context of non-small cell lung cancer (NSCLC), AOX1 expression has been associated with tumor progression and may influence the efficacy of certain chemotherapeutic agents, potentially serving as a biomarker for treatment response. Elevated AOX1 levels have been linked to poorer survival outcomes, suggesting that it may play a role in tumor aggressiveness and patient prognosis.",
  "SUV39H2": "SUV39H2 is a gene that encodes a histone methyltransferase involved in the regulation of chromatin structure and gene expression. In the context of non-small cell lung cancer (NSCLC), elevated expression of SUV39H2 has been associated with poor prognosis, as it may promote tumor progression and metastasis through epigenetic modifications. Consequently, targeting SUV39H2 could offer a novel therapeutic strategy, potentially improving survival outcomes for patients with aggressive NSCLC phenotypes.",
  "PSME4": "PSME4 (Proteasome Activator Subunit 4) is a gene that encodes a protein involved in the regulation of the proteasome, which plays a critical role in protein degradation and cellular homeostasis. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of PSME4 have been associated with poor prognosis, potentially due to its role in promoting tumor cell survival and resistance to apoptosis. Consequently, PSME4 may influence patient survival outcomes by contributing to tumor aggressiveness and treatment resistance, making it a potential biomarker for stratifying NSCLC patients for more tailored therapeutic approaches.",
  "SIGLEC1": "SIGLEC1 (Sialic Acid Binding Ig-like Lectin 1) is a gene that encodes a protein involved in immune regulation, particularly in the modulation of macrophage activity and the tumor microenvironment. In the context of non-small cell lung cancer (NSCLC), elevated expression of SIGLEC1 has been associated with poor prognosis, as it may facilitate immune evasion by tumors, thereby influencing treatment responses and overall survival outcomes. Targeting SIGLEC1 or its pathways could potentially enhance anti-tumor immunity and improve survival rates in NSCLC patients.",
  "BNIP2": "BNIP2 (Bcl-2/adenovirus E1B 19 kDa interacting protein 2) is a pro-apoptotic gene that plays a role in regulating cell death and survival pathways in non-small cell lung cancer (NSCLC). Its expression has been associated with tumor progression and poor prognosis, as it may influence the sensitivity of NSCLC cells to chemotherapy and targeted therapies. Elevated levels of BNIP2 could correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for treatment response and overall prognosis in NSCLC.",
  "AGGF1": "AGGF1 (Angiogenic Factor with G-patch and FHA Domains 1) is a gene implicated in angiogenesis and endothelial cell function, which plays a critical role in tumor growth and metastasis in non-small cell lung cancer (NSCLC). Elevated expression levels of AGGF1 have been associated with poor prognosis, as it may enhance tumor vascularization and support aggressive cancer phenotypes. Consequently, targeting AGGF1 or its pathways could offer therapeutic strategies to improve survival outcomes in NSCLC patients by potentially inhibiting tumor progression and metastasis.",
  "SCLY": "SCLY (Selenocysteine Lyase) is a gene involved in selenium metabolism and antioxidant defense, which has been implicated in the regulation of oxidative stress in non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and patient prognosis, where higher SCLY expression may correlate with poorer survival outcomes due to enhanced tumor resilience against oxidative damage. Understanding SCLY's role could inform therapeutic strategies targeting oxidative stress pathways, potentially improving treatment responses and survival rates in NSCLC patients.",
  "PIK3R1": "PIK3R1 encodes the regulatory subunit of phosphoinositide 3-kinase (PI3K), a key component of the PI3K/Akt signaling pathway, which is often dysregulated in non-small cell lung cancer (NSCLC). Alterations in PIK3R1, such as mutations or loss of expression, have been associated with poor prognosis and resistance to targeted therapies, potentially leading to decreased survival outcomes in NSCLC patients. Understanding PIK3R1 status may help guide treatment decisions and stratify patients for more personalized therapeutic approaches.",
  "PSD": "The feature \"PSD\" refers to the \"phosphorylation site domain,\" which encompasses specific regions within proteins that are modified by phosphorylation, influencing their function and signaling pathways. In the context of non-small cell lung cancer (NSCLC), PSDs are significant as they can affect tumor growth, metastasis, and response to targeted therapies, thereby serving as potential biomarkers for prognosis. Alterations in PSD-related signaling pathways may correlate with patient survival outcomes, as they can impact treatment efficacy and disease progression, making them critical for personalized therapeutic strategies.",
  "ZNF135": "ZNF135 is a gene that encodes a zinc finger protein, which is involved in transcriptional regulation and may play a role in cellular processes such as proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of ZNF135 has been associated with poor prognosis, potentially influencing tumor aggressiveness and response to therapy. Elevated levels of ZNF135 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "ZNF518A": "ZNF518A is a gene that encodes a zinc finger protein, which is involved in transcriptional regulation and may play a role in tumorigenesis. In the context of non-small cell lung cancer (NSCLC), alterations in ZNF518A expression have been associated with poor prognosis, potentially influencing tumor growth and metastasis. Elevated levels of ZNF518A may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more aggressive treatment approaches.",
  "MRPS18B": "MRPS18B is a gene encoding a mitochondrial ribosomal protein that plays a crucial role in mitochondrial protein synthesis. In the context of non-small cell lung cancer (NSCLC), altered expression of MRPS18B has been associated with tumor progression and poor prognosis, potentially influencing pathways related to cellular metabolism and apoptosis. Elevated levels of MRPS18B may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "SYTL2": "SYTL2 (Synaptotagmin-like 2) is a gene that encodes a protein involved in intracellular trafficking and signaling pathways. In the context of non-small cell lung cancer (NSCLC), SYTL2 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Elevated SYTL2 expression could influence patient survival by promoting aggressive tumor behavior, making it a potential biomarker for stratifying NSCLC patients for targeted therapies or more intensive treatment approaches.",
  "LILRB2": "LILRB2 (Leukocyte Immunoglobulin-Like Receptor B2) is a gene that encodes an immune checkpoint receptor involved in modulating immune responses. In the context of non-small cell lung cancer (NSCLC), LILRB2 has been associated with tumor immune evasion and poor prognosis, as its expression can inhibit T-cell activation and promote an immunosuppressive tumor microenvironment. Elevated levels of LILRB2 may correlate with reduced patient survival outcomes, highlighting its potential as a therapeutic target for enhancing anti-tumor immunity in NSCLC treatment strategies.",
  "PLEKHA6": "PLEKHA6 is a gene that encodes a protein involved in cellular signaling and membrane trafficking, which has been implicated in various cancer processes, including NSCLC. Its expression levels have been associated with tumor progression and patient prognosis, where higher PLEKHA6 expression may correlate with poorer survival outcomes due to its role in promoting cancer cell proliferation and metastasis. Understanding PLEKHA6's impact on NSCLC could inform treatment strategies and help identify patients at higher risk for aggressive disease.",
  "PSORS1C1": "PSORS1C1 is a gene located within the psoriasis susceptibility locus 1, and it has been implicated in immune response regulation. In the context of non-small cell lung cancer (NSCLC), alterations in PSORS1C1 expression may influence tumor microenvironment interactions and immune evasion, potentially affecting patient prognosis. Elevated levels of PSORS1C1 have been associated with poorer survival outcomes, suggesting that it could serve as a biomarker for stratifying NSCLC patients based on their risk and guiding therapeutic decisions.",
  "PSME3IP1": "PSME3IP1 is a gene that encodes a protein involved in the regulation of the proteasome, which plays a critical role in protein degradation and cellular homeostasis. In the context of non-small cell lung cancer (NSCLC), alterations in PSME3IP1 expression have been associated with tumor progression and poor prognosis, potentially influencing the efficacy of targeted therapies and immunotherapy. Elevated levels of PSME3IP1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and treatment response.",
  "CTSZ": "CTSZ (cathepsin Z) is a lysosomal cysteine protease gene that has been implicated in the tumor microenvironment of non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and poor prognosis, potentially influencing cancer cell invasion and metastasis. Elevated CTSZ expression may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding therapeutic decisions.",
  "PPIEL": "PPIEL (Peptidylprolyl Isomerase E-like) is a gene that encodes a protein involved in protein folding and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), altered expression of PPIEL has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Elevated levels of PPIEL may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "IL10": "IL10 (Interleukin-10) is a cytokine gene that plays a crucial role in immune regulation and inflammation. In the context of non-small cell lung cancer (NSCLC), elevated IL10 levels have been associated with an immunosuppressive tumor microenvironment, which can lead to poorer prognosis and reduced efficacy of immunotherapies. Consequently, IL10 expression may serve as a potential biomarker for patient stratification and could influence survival outcomes by modulating immune responses against tumor cells.",
  "PKNOX2": "PKNOX2 is a gene that encodes a homeobox protein involved in regulating developmental processes and cellular differentiation. In the context of non-small cell lung cancer (NSCLC), altered expression of PKNOX2 has been associated with tumor progression and poor prognosis, potentially influencing pathways related to cell proliferation and apoptosis. Elevated levels of PKNOX2 may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying risk and guiding therapeutic decisions in NSCLC management.",
  "SURF1": "SURF1 (Surfeit 1) is a gene that encodes a protein involved in mitochondrial function and energy metabolism. In the context of non-small cell lung cancer (NSCLC), alterations in SURF1 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies targeting metabolic pathways. Elevated SURF1 levels may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their prognosis and therapeutic options.",
  "CARD14": "CARD14 (Caspase Recruitment Domain Family Member 14) is a gene that encodes a protein involved in the regulation of inflammatory pathways, particularly the NF-\u03baB signaling pathway. In the context of non-small cell lung cancer (NSCLC), CARD14 has been implicated in tumor progression and immune response modulation, with studies suggesting that its expression levels may correlate with poor prognosis and resistance to certain therapies. Elevated CARD14 expression could influence patient survival outcomes by promoting tumor aggressiveness and immune evasion, thereby impacting treatment efficacy and overall survival rates.",
  "LRRN3": "LRRN3 (Leucine-Rich Repeat Neuronal 3) is a gene that has been implicated in various cellular processes, including cell adhesion and signaling. In the context of non-small cell lung cancer (NSCLC), alterations in LRRN3 expression have been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated levels of LRRN3 may correlate with poorer survival outcomes, influencing treatment decisions and highlighting the need for further investigation into its role in NSCLC therapeutic strategies.",
  "DAZAP2": "DAZAP2 (DAZ Associated Protein 2) is a gene implicated in RNA processing and regulation, which has been associated with various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been correlated with tumor aggressiveness and patient prognosis, suggesting that higher DAZAP2 expression may be linked to poorer survival outcomes in NSCLC patients. Understanding the role of DAZAP2 in tumor biology could provide insights into potential therapeutic targets and help stratify patients based on their risk profiles for more personalized treatment approaches.",
  "PAK1": "PAK1 (p21-activated kinase 1) is a serine/threonine kinase that plays a critical role in various cellular processes, including cell proliferation, survival, and migration, making it a key player in the pathogenesis of non-small cell lung cancer (NSCLC). Elevated PAK1 expression has been associated with poor prognosis in NSCLC patients, as it may promote tumor growth and metastasis, thereby influencing treatment resistance and overall survival outcomes. Targeting PAK1 could offer a potential therapeutic strategy to improve survival rates in NSCLC patients by inhibiting its oncogenic signaling pathways.",
  "PCBD1": "PCBD1 (pterin-4-alpha-carbinolamine dehydratase) is a gene involved in the metabolism of tetrahydrobiopterin, which plays a role in neurotransmitter synthesis and cellular redox balance. In the context of non-small cell lung cancer (NSCLC), altered expression of PCBD1 has been associated with tumor progression and may influence the efficacy of targeted therapies, potentially serving as a prognostic biomarker. Elevated levels of PCBD1 expression have been linked to poorer survival outcomes, suggesting that it may contribute to tumor aggressiveness and resistance to treatment, thereby impacting patient survival.",
  "RUBCNL": "RUBCNL (RUBCNL gene) is a gene implicated in the regulation of cellular processes such as apoptosis and cell cycle progression, which are critical in the context of non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and patient prognosis, where higher RUBCNL expression may correlate with poorer survival outcomes due to enhanced tumor proliferation and resistance to therapy. Understanding RUBCNL's role could inform treatment strategies and risk stratification in NSCLC patients, potentially guiding targeted therapies and improving survival rates.",
  "UBFD1": "UBFD1 (Ubiquitin-Fold Domain Containing 1) is a gene implicated in the regulation of protein degradation and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), altered expression of UBFD1 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Elevated levels of UBFD1 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "PLOD2": "PLOD2 (Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 2) is a gene involved in collagen biosynthesis and extracellular matrix remodeling, which plays a critical role in tumor progression and metastasis in non-small cell lung cancer (NSCLC). Elevated expression of PLOD2 has been associated with poor prognosis, as it may enhance tumor invasiveness and promote a more aggressive phenotype. Consequently, high PLOD2 levels could negatively influence patient survival outcomes by facilitating tumor spread and resistance to therapies.",
  "MAP1LC3C": "MAP1LC3C is a gene that encodes a protein involved in the autophagy pathway, which plays a critical role in cellular homeostasis and response to stress. In the context of non-small cell lung cancer (NSCLC), elevated expression of MAP1LC3C has been associated with poor prognosis, as it may facilitate tumor growth and resistance to therapies by promoting autophagic survival mechanisms. Consequently, high levels of MAP1LC3C expression could negatively influence patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "TRMT1": "TRMT1 (tRNA methyltransferase 1) is a gene involved in the post-transcriptional modification of tRNA, which is crucial for protein synthesis. In the context of non-small cell lung cancer (NSCLC), altered expression of TRMT1 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of certain therapies. Elevated TRMT1 levels may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "GNA12": "GNA12 is a gene that encodes a G protein involved in various signaling pathways, including those regulating cell proliferation and survival. In the context of non-small cell lung cancer (NSCLC), alterations in GNA12 have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Its expression levels and mutational status may serve as prognostic biomarkers, helping to stratify patients based on survival outcomes and guiding therapeutic decisions.",
  "WSCD1": "WSCD1 (WSC domain-containing 1) is a gene implicated in cellular signaling pathways that may influence tumor microenvironment interactions in non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and patient prognosis, where higher WSCD1 expression may correlate with poorer survival outcomes. Understanding WSCD1's role could provide insights into potential therapeutic targets and stratification of patients for more personalized treatment approaches in NSCLC.",
  "PUM1": "PUM1 (Pumilio RNA-binding family member 1) is a gene that encodes a protein involved in post-transcriptional regulation of gene expression, influencing various cellular processes, including proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), PUM1 has been associated with poor prognosis, as its overexpression may contribute to tumor progression and resistance to therapies. Elevated levels of PUM1 can negatively impact patient survival outcomes by promoting aggressive tumor behavior and limiting the effectiveness of treatment strategies.",
  "HAUS2": "HAUS2 (Hauck et al. 2) is a gene that encodes a protein involved in the regulation of microtubule dynamics and is part of the HAUS (Hauck and associates) complex, which plays a critical role in mitosis. In the context of non-small cell lung cancer (NSCLC), elevated expression of HAUS2 has been associated with poor prognosis, as it may contribute to increased cell proliferation and tumor aggressiveness. Consequently, HAUS2 expression levels could serve as a potential biomarker for survival outcomes, influencing treatment decisions and patient management strategies in NSCLC.",
  "ATP1B2": "ATP1B2 encodes the beta subunit of the Na+/K+ ATPase, a critical enzyme involved in maintaining cellular ion homeostasis. In the context of non-small cell lung cancer (NSCLC), altered expression of ATP1B2 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and chemotherapy. Elevated levels of ATP1B2 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "PGA5": "PGA5 (Pepsinogen A5) is a gene that encodes a precursor of pepsin, an enzyme involved in protein digestion, and has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor aggressiveness and may serve as a potential biomarker for prognosis, influencing treatment decisions and patient stratification. Elevated PGA5 expression has been linked to poorer survival outcomes in NSCLC patients, suggesting its role in tumor progression and the potential for targeted therapeutic strategies.",
  "RFX3": "RFX3 (Regulatory Factor X3) is a transcription factor that has been implicated in the regulation of immune responses and cellular differentiation. In the context of non-small cell lung cancer (NSCLC), altered expression of RFX3 has been associated with tumor progression and poor prognosis, potentially influencing the tumor microenvironment and immune evasion. Elevated levels of RFX3 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and a target for therapeutic strategies aimed at enhancing anti-tumor immunity.",
  "S1PR2": "S1PR2 (Sphingosine-1-phosphate receptor 2) is a G protein-coupled receptor that plays a critical role in cell signaling pathways associated with tumor progression and immune response modulation in non-small cell lung cancer (NSCLC). Elevated expression of S1PR2 has been linked to poor prognosis, as it may promote tumor cell proliferation, migration, and resistance to apoptosis, thereby influencing patient survival outcomes negatively. Targeting S1PR2 could offer a potential therapeutic strategy to improve treatment responses and overall survival in NSCLC patients.",
  "ITGB5": "ITGB5 encodes integrin beta-5, a protein that plays a crucial role in cell adhesion and signaling within the tumor microenvironment. In non-small cell lung cancer (NSCLC), elevated expression of ITGB5 has been associated with poor prognosis, as it may promote tumor invasion and metastasis. Targeting ITGB5 could potentially enhance therapeutic strategies and improve survival outcomes by disrupting these pro-tumorigenic pathways.",
  "YARS2": "YARS2 (tyrosyl-tRNA synthetase 2) is a gene involved in mitochondrial protein synthesis and has been implicated in the regulation of oxidative stress and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of YARS2 has been associated with poor prognosis, potentially influencing tumor growth and resistance to therapies. Elevated levels of YARS2 may correlate with decreased patient survival outcomes, highlighting its potential as a biomarker for stratifying risk and guiding treatment decisions in NSCLC.",
  "VPS16": "VPS16 (Vacuolar Protein Sorting 16) is a gene involved in the endosomal-lysosomal pathway, playing a critical role in autophagy and cellular degradation processes. In the context of non-small cell lung cancer (NSCLC), altered expression of VPS16 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies and immunotherapy. Elevated VPS16 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "MSC": "The feature \"MSC\" refers to the mesenchymal stem cell marker, which is associated with the tumor microenvironment in non-small cell lung cancer (NSCLC). Elevated MSC expression has been linked to tumor progression, metastasis, and poor prognosis, as it may promote epithelial-to-mesenchymal transition (EMT) and enhance cancer stem cell properties. Consequently, high MSC levels could negatively influence patient survival outcomes by contributing to treatment resistance and aggressive disease behavior.",
  "LGALS4": "LGALS4 (Lectin, Galactoside-Binding, Soluble, 4) is a gene that encodes a galectin protein involved in immune modulation and tumor progression. In the context of non-small cell lung cancer (NSCLC), elevated expression of LGALS4 has been associated with poor prognosis, potentially due to its role in promoting tumor immune evasion and metastasis. Consequently, targeting LGALS4 may offer therapeutic avenues to improve survival outcomes by enhancing anti-tumor immunity in NSCLC patients.",
  "SEMG2": "SEMG2 (Semenogelin II) is a gene that encodes a protein involved in the regulation of extracellular matrix components and has been implicated in tumor progression. In the context of non-small cell lung cancer (NSCLC), altered expression levels of SEMG2 have been associated with poor prognosis, potentially influencing tumor invasiveness and metastasis. Elevated SEMG2 expression may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more aggressive treatment approaches.",
  "RELN": "RELN (Reelin) is a gene that encodes a protein involved in neuronal migration and synaptic plasticity, but emerging evidence suggests it also plays a role in tumor biology, including non-small cell lung cancer (NSCLC). In the context of NSCLC, altered expression of RELN has been associated with tumor progression and metastasis, potentially influencing patient prognosis. Higher levels of RELN expression may correlate with poorer survival outcomes, making it a candidate for further investigation as a prognostic biomarker and therapeutic target in NSCLC management.",
  "GREB1": "GREB1 (Growth Regulation by Estrogen in Breast Cancer 1) is a gene that has been implicated in the regulation of estrogen signaling and is associated with tumor growth in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been correlated with poor prognosis and may influence treatment responses, particularly in patients with hormone receptor-positive tumors. Elevated GREB1 expression could potentially serve as a biomarker for aggressive disease and may inform therapeutic strategies, impacting overall patient survival outcomes.",
  "TCP11L1": "TCP11L1 (TCP11-like 1) is a gene that has been implicated in the regulation of cellular processes such as proliferation and apoptosis, which are critical in the context of non-small cell lung cancer (NSCLC). Elevated expression levels of TCP11L1 have been associated with poor prognosis in NSCLC patients, potentially influencing tumor aggressiveness and resistance to therapies. Understanding its role could aid in stratifying patients for more personalized treatment approaches and improving survival outcomes through targeted interventions.",
  "CCNC": "CCNC (Cyclin C) is a gene that encodes a regulatory subunit of cyclin-dependent kinases, playing a crucial role in cell cycle regulation. In the context of non-small cell lung cancer (NSCLC), altered expression of CCNC has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of CCNC may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and guiding therapeutic decisions.",
  "ZFAND1": "ZFAND1 is a gene that encodes a protein involved in the regulation of the ubiquitin-proteasome system, which plays a critical role in protein degradation and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), altered expression of ZFAND1 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of targeted therapies and immunotherapy. Elevated levels of ZFAND1 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and treatment response.",
  "ACSL1": "ACSL1 (Acyl-CoA Synthetase Long-Chain Family Member 1) is a gene involved in fatty acid metabolism and has been implicated in the metabolic reprogramming of cancer cells, including non-small cell lung cancer (NSCLC). Elevated expression of ACSL1 has been associated with poor prognosis in NSCLC patients, as it may promote tumor growth and resistance to therapies by enhancing lipid synthesis and supporting cancer cell survival. Consequently, ACSL1 expression levels could serve as a potential biomarker for predicting patient survival outcomes and guiding therapeutic strategies in NSCLC.",
  "RABL6": "RABL6 is a gene that encodes a protein involved in cell cycle regulation and has been implicated in oncogenic processes. In the context of non-small cell lung cancer (NSCLC), elevated expression of RABL6 has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Its role as a prognostic biomarker suggests that RABL6 expression levels could help stratify patients for more tailored therapeutic approaches, ultimately impacting survival outcomes.",
  "MS4A6A": "MS4A6A is a gene that encodes a member of the membrane-spanning 4-domains, subfamily A, which is involved in immune regulation. In the context of non-small cell lung cancer (NSCLC), MS4A6A has been associated with tumor microenvironment modulation and immune response, potentially influencing the efficacy of immunotherapies. Elevated expression levels of MS4A6A may correlate with improved survival outcomes in NSCLC patients, suggesting its potential as a prognostic biomarker and therapeutic target in enhancing treatment responses.",
  "GPR162": "GPR162 is a G protein-coupled receptor gene that has been implicated in various signaling pathways associated with tumorigenesis. In the context of non-small cell lung cancer (NSCLC), altered expression of GPR162 has been linked to poor prognosis, potentially influencing tumor growth and metastasis. Its role in modulating the tumor microenvironment may affect patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for targeted therapies.",
  "FCGR1A": "FCGR1A (Fc gamma receptor I A) is a gene that encodes a receptor involved in the immune response, specifically mediating the effects of antibodies on immune cells. In the context of non-small cell lung cancer (NSCLC), variations in FCGR1A expression have been associated with differential responses to immunotherapy and targeted treatments, influencing tumor microenvironment interactions. Higher expression levels of FCGR1A may correlate with improved patient survival outcomes, as they can enhance antibody-dependent cellular cytotoxicity against tumor cells, thereby potentially improving therapeutic efficacy.",
  "BEGAIN": "BEGAIN (B-cell receptor signaling pathway gene) is a gene that has been implicated in the regulation of immune responses and tumor microenvironment interactions in non-small cell lung cancer (NSCLC). Its expression levels have been associated with patient prognosis, where higher BEGAIN expression may correlate with improved survival outcomes due to enhanced anti-tumor immunity. Understanding BEGAIN's role could inform treatment strategies, particularly in the context of immunotherapy, by identifying patients who may benefit from immune checkpoint inhibitors.",
  "NES": "NES, or Normalized Enrichment Score, represents the degree to which a gene set is overrepresented in a given sample compared to a reference set, often derived from pathway analyses. In the context of non-small cell lung cancer (NSCLC), NES can indicate the activation or repression of specific biological pathways associated with tumor progression, response to therapy, and overall prognosis. Higher NES values for certain oncogenic pathways may correlate with poorer survival outcomes, guiding treatment decisions and stratifying patients for targeted therapies or clinical trials.",
  "TCF4": "TCF4 (Transcription Factor 4) is a gene that encodes a transcription factor involved in various cellular processes, including cell proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), TCF4 has been implicated in tumor progression and metastasis, with studies suggesting that its expression levels may correlate with poor prognosis and reduced survival outcomes. Targeting TCF4 or its downstream pathways could offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "YIF1A": "YIF1A is a gene that encodes a protein involved in the regulation of intracellular transport and has been implicated in the endoplasmic reticulum stress response. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of YIF1A have been associated with poor prognosis, potentially influencing tumor growth and resistance to therapies. Its role in modulating the tumor microenvironment and response to treatment may significantly impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for targeted therapies.",
  "FRMD1": "FRMD1 (FERM domain-containing protein 1) is a gene implicated in cellular signaling pathways and cytoskeletal organization, which has been associated with tumor progression in non-small cell lung cancer (NSCLC). Its expression levels have been correlated with patient prognosis, where higher FRMD1 expression may indicate a more aggressive tumor phenotype and poorer survival outcomes. Understanding FRMD1's role could inform treatment strategies, as targeting its pathways may enhance therapeutic efficacy and improve patient survival in NSCLC.",
  "TMEM63A": "TMEM63A is a gene that encodes a transmembrane protein involved in cellular processes such as ion transport and cell signaling. In the context of non-small cell lung cancer (NSCLC), alterations in TMEM63A expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of TMEM63A may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients in clinical settings.",
  "PFDN4": "PFDN4 (Prefoldin 4) is a gene that encodes a protein involved in the chaperoning of nascent polypeptides, playing a critical role in protein folding and cellular stress responses. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of PFDN4 have been associated with poor prognosis, potentially influencing tumor growth and resistance to therapies. Its modulation may impact patient survival outcomes by affecting tumor aggressiveness and response to treatment, making it a potential biomarker for stratifying NSCLC patients in clinical settings.",
  "ETV1": "ETV1 is an oncogene that encodes a transcription factor involved in the regulation of genes associated with cell proliferation and survival. In the context of non-small cell lung cancer (NSCLC), ETV1 has been implicated in tumor progression and metastasis, with elevated expression levels correlating with poor prognosis and reduced survival outcomes. Targeting ETV1 or its downstream pathways may offer therapeutic strategies to improve patient survival, particularly in cases where ETV1 is overexpressed.",
  "KIR3DS1": "KIR3DS1 is a gene encoding a receptor involved in the immune response, specifically within the natural killer (NK) cell pathway. In the context of non-small cell lung cancer (NSCLC), KIR3DS1 has been associated with improved prognosis, as its expression may enhance NK cell-mediated cytotoxicity against tumor cells. Consequently, higher levels of KIR3DS1 expression could correlate with better patient survival outcomes, potentially influencing treatment strategies that leverage immune modulation.",
  "SEC24B": "SEC24B is a gene that encodes a protein involved in the transport of proteins from the endoplasmic reticulum to the Golgi apparatus, playing a crucial role in cellular secretion processes. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of SEC24B have been associated with poor prognosis, potentially influencing tumor aggressiveness and metastasis. Its role in modulating the tumor microenvironment and response to therapies may impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for more personalized treatment approaches.",
  "CXCL14": "CXCL14 is a chemokine gene that plays a role in immune cell recruitment and modulation within the tumor microenvironment. In the context of non-small cell lung cancer (NSCLC), elevated CXCL14 expression has been associated with improved prognosis, potentially due to its involvement in enhancing anti-tumor immune responses. By influencing tumor-infiltrating lymphocyte dynamics, CXCL14 may serve as a biomarker for patient survival outcomes, guiding therapeutic strategies that leverage immune modulation.",
  "STXBP2": "STXBP2 (Syntaxin Binding Protein 2) is a gene involved in the regulation of exocytosis and immune response, which has been implicated in the pathogenesis of non-small cell lung cancer (NSCLC). Alterations in STXBP2 expression have been associated with tumor progression and immune evasion, potentially influencing the effectiveness of immunotherapies. Higher expression levels of STXBP2 may correlate with improved survival outcomes in NSCLC patients, suggesting its potential as a prognostic biomarker and therapeutic target.",
  "RFXAP": "RFXAP (Regulatory Factor X Associated Protein) is a gene involved in the regulation of immune responses and antigen presentation. In the context of non-small cell lung cancer (NSCLC), RFXAP has been associated with tumor immune microenvironment modulation, influencing the efficacy of immunotherapies. Elevated expression levels of RFXAP may correlate with improved patient survival outcomes, potentially serving as a prognostic biomarker for treatment response and overall survival in NSCLC patients.",
  "NEDD4L": "NEDD4L (Neural Precursor Cell Expressed Developmentally Downregulated 4-Like) is a gene that encodes an E3 ubiquitin ligase involved in the regulation of various cellular processes, including apoptosis and cell proliferation. In the context of non-small cell lung cancer (NSCLC), altered expression of NEDD4L has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of targeted therapies. High levels of NEDD4L expression may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "TMEM62": "TMEM62 is a gene that encodes a transmembrane protein implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of TMEM62 has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Its role in modulating the tumor microenvironment may affect patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients for targeted therapies.",
  "RPL32": "RPL32 is a ribosomal protein gene that plays a crucial role in protein synthesis and cellular growth. In the context of non-small cell lung cancer (NSCLC), elevated expression levels of RPL32 have been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapy. Its expression may serve as a biomarker for survival outcomes, where higher levels could indicate a more unfavorable clinical course, guiding treatment decisions and patient management strategies.",
  "BAIAP2L2": "BAIAP2L2 (Baiap2-Like 2) is a gene that encodes a protein involved in cellular signaling and cytoskeletal organization. In the context of non-small cell lung cancer (NSCLC), altered expression of BAIAP2L2 has been associated with tumor progression and metastasis, potentially serving as a prognostic biomarker. Elevated levels of BAIAP2L2 may correlate with poorer survival outcomes, influencing treatment decisions and patient management strategies in NSCLC.",
  "SETD1B": "SETD1B is a gene encoding a histone methyltransferase involved in the regulation of gene expression through chromatin modification. In the context of non-small cell lung cancer (NSCLC), alterations in SETD1B have been associated with poor prognosis, as they may contribute to tumorigenesis and resistance to therapies. Its expression levels and mutational status could serve as potential biomarkers for predicting patient survival outcomes and guiding treatment strategies.",
  "BCL6": "BCL6 is a gene that encodes a transcriptional repressor involved in the regulation of immune responses and cell proliferation. In the context of non-small cell lung cancer (NSCLC), aberrant expression of BCL6 has been associated with tumor progression and poor prognosis, potentially influencing the effectiveness of targeted therapies and immunotherapies. Elevated BCL6 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "INVS": "INVS (inversin) is a gene that encodes a protein involved in the regulation of the Wnt signaling pathway, which plays a critical role in cell proliferation and differentiation. In the context of non-small cell lung cancer (NSCLC), altered expression of INVS has been associated with poor prognosis, as it may contribute to tumor aggressiveness and resistance to therapies. Elevated levels of INVS expression can negatively influence patient survival outcomes by promoting tumor growth and metastasis, highlighting its potential as a biomarker for stratifying NSCLC patients for more tailored treatment approaches.",
  "DBNDD1": "DBNDD1 (Dab2 Interacting Protein) is a gene that has been implicated in various cellular processes, including cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of DBNDD1 has been associated with poor prognosis, potentially influencing tumor growth and metastasis. Its role as a prognostic biomarker suggests that higher levels of DBNDD1 expression may correlate with reduced patient survival outcomes, making it a potential target for therapeutic intervention and stratification in NSCLC treatment.",
  "YBX1": "YBX1 (Y-box binding protein 1) is a gene that encodes a transcription factor involved in various cellular processes, including proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), elevated YBX1 expression has been associated with poor prognosis, as it can promote tumor growth and resistance to chemotherapy. Consequently, high levels of YBX1 may negatively influence patient survival outcomes by contributing to aggressive tumor behavior and treatment resistance, making it a potential biomarker for stratifying NSCLC patients for targeted therapies.",
  "TRAF3IP2": "TRAF3IP2 (TNF Receptor-Associated Factor 3 Interacting Protein 2) is a gene that plays a role in the regulation of immune responses and inflammation. In the context of non-small cell lung cancer (NSCLC), TRAF3IP2 has been implicated in tumor progression and immune evasion, with studies suggesting that its expression levels may correlate with patient prognosis. Elevated TRAF3IP2 expression has been associated with poorer survival outcomes, potentially influencing treatment strategies that target immune pathways in NSCLC patients.",
  "GALT": "GALT (galactose-1-phosphate uridylyltransferase) is a gene involved in galactose metabolism, and its expression levels have been implicated in the metabolic reprogramming of cancer cells, including non-small cell lung cancer (NSCLC). Alterations in GALT expression may influence tumor growth and response to therapies, potentially serving as a prognostic biomarker for patient survival outcomes. Higher GALT expression has been associated with improved survival rates, suggesting its role in modulating tumor aggressiveness and treatment efficacy in NSCLC patients.",
  "IL36RN": "IL36RN encodes the interleukin-36 receptor antagonist, a key regulator of the inflammatory response. In the context of non-small cell lung cancer (NSCLC), elevated IL36RN expression has been associated with a more favorable prognosis, potentially due to its role in modulating the tumor microenvironment and immune response. By influencing inflammatory pathways, IL36RN may impact patient survival outcomes, suggesting its potential as a biomarker for stratifying NSCLC patients and guiding immunotherapeutic strategies.",
  "OR7E24": "OR7E24 is a gene encoding an olfactory receptor that has been implicated in various cancers, including non-small cell lung cancer (NSCLC). While its direct role in NSCLC prognosis is not fully elucidated, alterations in olfactory receptor expression may influence tumor microenvironment interactions and immune responses, potentially affecting treatment outcomes. Understanding the expression levels of OR7E24 could provide insights into patient survival, as variations may correlate with tumor aggressiveness and response to targeted therapies.",
  "LEFTY1": "LEFTY1 is a gene that encodes a member of the transforming growth factor-beta (TGF-\u03b2) superfamily, which plays a role in embryonic development and cellular signaling. In the context of non-small cell lung cancer (NSCLC), LEFTY1 has been implicated in tumor progression and metastasis, with elevated expression levels associated with poor prognosis and reduced survival outcomes. Targeting LEFTY1 or its signaling pathways may offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "PARP16": "PARP16 is a gene that encodes a member of the poly(ADP-ribose) polymerase family, which is involved in cellular stress responses and protein quality control. In the context of non-small cell lung cancer (NSCLC), PARP16 has been implicated in DNA repair mechanisms and may influence tumor sensitivity to therapies targeting DNA damage response pathways. Elevated expression of PARP16 has been associated with poorer prognosis in NSCLC patients, potentially impacting survival outcomes by affecting tumor aggressiveness and treatment resistance.",
  "ADCYAP1": "ADCYAP1 (Adenylate Cyclase Activating Polypeptide 1) is a gene that encodes a neuropeptide involved in various signaling pathways, including those regulating cell proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of ADCYAP1 has been associated with tumor progression and may serve as a prognostic biomarker, influencing treatment responses and survival outcomes. Higher levels of ADCYAP1 expression have been linked to improved survival rates, suggesting its potential role in therapeutic strategies targeting neuropeptide signaling pathways in NSCLC patients.",
  "CPNE3": "CPNE3 (Copine 3) is a gene that encodes a calcium-dependent membrane-binding protein, which has been implicated in various cellular processes, including apoptosis and cell signaling. In the context of non-small cell lung cancer (NSCLC), altered expression of CPNE3 has been associated with tumor progression and poor prognosis, suggesting its potential role as a biomarker for survival outcomes. Elevated levels of CPNE3 may influence patient survival by promoting aggressive tumor behavior, thereby impacting treatment responses and overall survival rates in NSCLC patients.",
  "FCRL2": "FCRL2 (Fc receptor-like 2) is a gene that encodes a protein involved in immune regulation, particularly in modulating B cell responses. In the context of non-small cell lung cancer (NSCLC), elevated expression of FCRL2 has been associated with poor prognosis, potentially due to its role in promoting immune evasion by tumor cells. Understanding FCRL2's influence on immune dynamics may help identify patients who could benefit from immunotherapy, thereby impacting overall survival outcomes.",
  "TMEM187": "TMEM187 is a gene that encodes a transmembrane protein implicated in various cellular processes, including cell signaling and migration. In the context of non-small cell lung cancer (NSCLC), altered expression of TMEM187 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of TMEM187 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "ZC3H13": "ZC3H13 is a gene that encodes a zinc finger protein involved in RNA processing and regulation, which has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and patient prognosis, where higher ZC3H13 expression may correlate with improved survival outcomes due to its potential role in modulating immune responses and tumor microenvironment interactions. Understanding ZC3H13's function could provide insights into targeted therapies and stratification of NSCLC patients based on their survival likelihood.",
  "BAG1": "BAG1 (Bcl-2-associated athanogene 1) is a gene that encodes a protein involved in regulating apoptosis and cellular stress responses, playing a role in tumorigenesis. In the context of non-small cell lung cancer (NSCLC), elevated BAG1 expression has been associated with poor prognosis, as it may contribute to tumor cell survival and resistance to chemotherapy. Consequently, high levels of BAG1 could negatively influence patient survival outcomes by promoting tumor aggressiveness and limiting treatment efficacy.",
  "LINC00667": "LINC00667 is a long non-coding RNA (lncRNA) that has been implicated in the regulation of gene expression and cellular processes in non-small cell lung cancer (NSCLC). Studies suggest that elevated levels of LINC00667 are associated with poor prognosis, potentially influencing tumor growth, metastasis, and resistance to therapies. Its expression profile may serve as a prognostic biomarker, helping to stratify patients based on survival outcomes and guiding treatment decisions in NSCLC management.",
  "POU5F1P4": "POU5F1P4, also known as a pseudogene of the POU class 5 homeobox 1 (POU5F1), is implicated in the regulation of pluripotency and stem cell characteristics, which can influence tumorigenesis in non-small cell lung cancer (NSCLC). Its expression has been associated with poor prognosis, as higher levels may correlate with increased tumor aggressiveness and resistance to therapies. Consequently, POU5F1P4 may serve as a potential biomarker for stratifying NSCLC patients based on survival outcomes and guiding treatment decisions.",
  "SPART": "SPART (SPA-related protein) is a gene that encodes a protein involved in cellular signaling and cytoskeletal organization. In the context of non-small cell lung cancer (NSCLC), altered expression of SPART has been associated with tumor progression and poor prognosis, potentially influencing pathways related to cell proliferation and metastasis. Elevated levels of SPART may correlate with reduced patient survival outcomes, making it a potential biomarker for stratifying risk and guiding therapeutic decisions in NSCLC management.",
  "ASCC3": "ASCC3 (Activating Signal Cointegrator 3) is a gene involved in the regulation of cellular signaling pathways and has been implicated in various cancers, including non-small cell lung cancer (NSCLC). Its expression levels have been associated with tumor progression and patient prognosis, where higher ASCC3 expression may correlate with poor survival outcomes due to its role in promoting cancer cell proliferation and resistance to therapy. Understanding ASCC3's impact on NSCLC could inform treatment strategies and help identify patients at higher risk for adverse outcomes.",
  "RAP2B": "RAP2B is a gene that encodes a member of the RAS oncogene family, which is involved in cell signaling pathways that regulate cell growth and differentiation. In the context of non-small cell lung cancer (NSCLC), altered expression of RAP2B has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of RAP2B may correlate with decreased patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "KCNF1": "KCNF1 (Potassium Voltage-Gated Channel Subfamily F Member 1) is a gene that encodes a voltage-gated potassium channel, which is involved in regulating cellular excitability and proliferation. In the context of non-small cell lung cancer (NSCLC), alterations in KCNF1 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated KCNF1 levels may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker in NSCLC management.",
  "SEC63": "SEC63 is a gene that encodes a protein involved in the endoplasmic reticulum (ER) stress response and protein folding. In the context of non-small cell lung cancer (NSCLC), altered expression of SEC63 has been associated with tumor progression and poor prognosis, potentially influencing the efficacy of targeted therapies and immunotherapy. Elevated SEC63 levels may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients and guiding treatment decisions.",
  "CRELD2": "CRELD2 (Cysteine-Rich EGF-Related Protein 2) is a gene implicated in cell adhesion and signaling pathways, which has been associated with tumor progression in non-small cell lung cancer (NSCLC). Elevated expression of CRELD2 has been linked to poor prognosis, potentially influencing tumor aggressiveness and metastasis, thereby adversely affecting patient survival outcomes. Understanding its role may provide insights into targeted therapies and stratification of NSCLC patients based on their risk profiles.",
  "GOLGA1": "GOLGA1 (Golgin A1) is a gene that encodes a protein involved in the organization of the Golgi apparatus and intracellular transport. In the context of non-small cell lung cancer (NSCLC), elevated expression of GOLGA1 has been associated with poor prognosis, potentially influencing tumor aggressiveness and resistance to therapies. Its role in modulating cellular processes such as proliferation and apoptosis may impact patient survival outcomes, making it a potential biomarker for stratifying NSCLC patients in clinical settings.",
  "KIF3A": "KIF3A (Kinesin Family Member 3A) is a gene that encodes a motor protein involved in intracellular transport and is implicated in various cellular processes, including cell division and signaling pathways. In the context of non-small cell lung cancer (NSCLC), KIF3A has been associated with tumor progression and metastasis, with studies suggesting that its overexpression correlates with poor prognosis and reduced survival outcomes. Targeting KIF3A or its associated pathways may offer potential therapeutic strategies to improve patient survival in NSCLC.",
  "SLC8A1": "SLC8A1 encodes a sodium/calcium exchanger that plays a critical role in cellular calcium homeostasis, which is essential for various cellular functions, including proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of SLC8A1 has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to therapies that target calcium signaling pathways. Elevated levels of SLC8A1 may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "INPP5A": "INPP5A (Inositol Polyphosphate-5-Phosphatase A) is a gene that encodes an enzyme involved in phosphoinositide signaling pathways, which are critical for various cellular processes, including proliferation and apoptosis. In the context of non-small cell lung cancer (NSCLC), altered expression of INPP5A has been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of INPP5A may correlate with reduced patient survival outcomes, highlighting its potential as a prognostic biomarker and therapeutic target in NSCLC management.",
  "IFT140": "IFT140 is a gene that encodes a protein involved in the intraflagellar transport pathway, which is crucial for ciliary function and cellular signaling. In the context of non-small cell lung cancer (NSCLC), alterations in IFT140 expression have been associated with tumor progression and poor prognosis, potentially influencing treatment responses to targeted therapies. Elevated levels of IFT140 may correlate with reduced patient survival outcomes, highlighting its potential as a biomarker for stratifying NSCLC patients based on their risk and therapeutic options."
}